



HARNESS
THE

MOMENTUM

AT THE 75th
LIVER
MEETING

PROGRAM GUIDE

AS OF OCTOBER 10, 2024

PRESIDENT'S WELCOME

As President of the American Association for the Study of Liver Diseases (AASLD), it is my distinct pleasure to extend to you a warm welcome to The Liver Meeting®.

This year marks a significant milestone in our organization's history as we celebrate the 75th anniversary of The Liver Meeting. Over the past seven and a half decades, AASLD has been at the forefront of advancing liver disease research, education, and patient care. Our annual meeting has served as a cornerstone event for hepatology professionals from around the globe to convene, collaborate, and exchange cutting-edge knowledge and expertise.

This year's theme, "Momentum," serves as a poignant reflection of the remarkable progress and growth that The Liver Meeting has experienced since its inception. It underscores the collective efforts of our community in propelling the field of hepatology forward, fueled by innovation, collaboration, and a shared commitment to excellence.

I'm also excited to share some highlights of what makes the 75th Liver Meeting an unforgettable experience:

- **TLM's State-of-the-Art** speakers showcase cutting-edge research and advancements in hepatology. These world-renowned experts deliver insightful presentations on the latest innovations and discoveries and emerging trends providing attendees with invaluable knowledge. From adaptive immunity in autoimmune disease, hepatic encephalopathy to lipotoxicity in the liver, and life after a liver transplantation, you won't want to miss hearing from leaders shaping the future of hepatology.
- **Special Interest Groups (SIGs)** foster collaboration among AASLD members, connecting scientists and healthcare professionals who share specialized interests in key areas of hepatology. SIGs community offer tailored TLM programming from education to social networking events that drive collaboration and knowledge sharing. Starting Friday through Monday, there will be a range of SIG activity, including SIG business meetings, a robust series of Community Conversations, and SIGs in The Park networking opportunities.
- **Networking** is a hallmark of The Liver Meeting, and I encourage you to explore the many opportunities to connect. Visit The Park to socialize with peers or enjoy a round of pickleball or mini golf. Stop by the Poster Hall or join a Community Conversation to exchange ideas with other attendees, including researchers, clinicians, patients, and advocates. Meet industry partners and discover the latest liver treatment technologies in the Exhibit Hall. By embracing diverse voices, The Liver Meeting fosters collaboration and drives innovation in patient care globally.

I am truly proud of how The Liver Meeting continues to innovate and establish itself as the global leader in hepatology. As we celebrate the 75th Liver Meeting, I am excited to share the most comprehensive program, featuring both regular and late-breaking abstracts, which includes over 2,400 posters, 2,600 abstracts (oral and poster presentations), and an extensive patient program built by the community.

As we convene in San Diego, I invite you to join us in celebrating AASLD's rich legacy and charting the course for the future of hepatology. Together, let us continue to make strides in advancing liver health and transforming patient care.

On behalf of the AASLD leadership, I extend my sincere gratitude for your continued support and participation in The Liver Meeting for what promises to be a truly memorable and impactful event.

Sincerely,
Ray Kim, MD, MBA, FAASLD
President, AASLD



AASLD'S GLOBAL FOOTPRINT

The 75th Liver Meeting is a global exchange representing speakers and attendees from over 65 countries.



AASLD PARTNERS

From Around the Globe Collaborating to Prevent and Cure Liver Disease



TABLE OF CONTENTS

Connecting On-site	4
Navigating TLM	5
AASLD Foundation	9
The 75th Liver Meeting Program	11
Explore Targeted Programming	55
Exhibitors & Sponsors	57
Note Pages	64



BAG & COAT CHECK

Located at Exhibit Hall B foyer, Bag & Coat Check is available Friday-Monday from 6:30 AM to 7:30 PM and Tuesday from 6:30 AM to 12:30 PM.



FIRST AID

First aid is available throughout the Convention Center. The first aid office is located in the Hall A foyer.



LOST & FOUND

Lost and left behind items may be found at registration, located in Hall A foyer. At the end of the meeting, all items will be turned into the San Diego Convention Center security.



WIFI

Complimentary WiFi is supported by Madrigal Pharmaceuticals and is available throughout the convention center.

Network Name/SSID: AASLD

Password: Madrigal



CONNECT WITH THE HEPATOLOGY COMMUNITY

Throughout your time at the 75th Liver Meeting, there are several opportunities to connect, collaborate, and forge new connections with fellow hepatology enthusiasts.



DOWNLOAD TLM'S MOBILE APP

Stay up to date with the latest session schedules, receive real-time notifications, and navigate the meeting with ease. The app is your all-in-one tool for maximizing your time at the conference—enhance your experience and download the official mobile app!

THE HUB

Make sure to visit AASLD's "The Hub" at The Liver Meeting! Here, you can grab the newest liver gear, explore AASLD's latest offerings, and check out the newest practice guidance and publications. It's the perfect spot to connect with AASLD resources and connect with others at the meeting. Don't miss out—stop by The Hub, booth #711!



EVENTS TO ATTEND

Friday, November 15

6:00-7:30 PM Convention Center, Hall A:
AASLD & AASLD Foundation Awards and Honors Ceremony

Saturday, November 16

6:00-6:45 PM Member Lounge, Room 4:
First-Time Attendee Reception

6:00-7:30 PM Convention Center, Exhibit Hall B:
Exhibit Hall Opening Reception
Supported by Mirum Pharmaceuticals

7:00-7:45 PM Member Lounge, Room 4:
Trainee Reception hosted by Liver Fellow Network

7:30-8:30 PM Marriott Marquis, San Diego Ballroom A:
PRIDE Reception

Sunday, November 17

5:45-6:45 PM Member Lounge, Room 4:
Hepatology Associates Reception

7:00-8:00 PM Marriott Marquis:
AASLD Annual Fellows' Reception

7:30-11:00 PM Marriott Marquis:
AASLD Members' Reception

Monday, November 18

6:30-7:30 PM Marriott Marquis, San Diego Ballroom A:
Diversity Reception
Supported by Medscape Education


NAVIGATING TLM

Use The Liver Meeting maps to help you navigate the conference space.



SAN DIEGO CONVENTION CENTER GROUND LEVEL

GROUND LEVEL








SAN DIEGO CONVENTION CENTER

MEZZANINE LEVEL

MEZZANINE LEVEL



- NEWSROOM
- SPEAKER READY ROOM
- QUIET/PRAYER ROOM



DOWNLOAD TLM'S MOBILE APP

For the most up-to-date information,
download the TLM mobile app.




NAVIGATING TLM

Use The Liver Meeting maps to help you navigate the conference space.



SAN DIEGO CONVENTION CENTER UPPER LEVEL

UPPER LEVEL





DOWNLOAD TLM'S MOBILE APP

Stay up to date with the latest session schedules, receive real-time notifications, and navigate the meeting with ease. The app is your all-in-one tool for maximizing your time at the conference—enhance your experience and download the official mobile app!

NEW EXHIBITOR PASSPORT

Returning for 2024, the New Exhibitor Passport game is distributed at registration and encourages attendees to visit **five new exhibitors** participating at the 75th Liver Meeting. Visit each booth, collect a sticker, and bring your passport to The AASLD Hub (booth 711) to be entered to win a free registration to The Liver Meeting® 2025!



AASLD FOUNDATION FUNDING THE HEPATOLOGY HEROES OF TOMORROW, TODAY!

The AASLD Foundation is committed to fostering innovation and excellence in liver disease training and research for liver healthcare providers to create a brighter and healthier tomorrow for liver disease patients and their families. Through career development and innovative research, AASLD Foundation remains at the heart of advancing the understanding and treatment of liver-related conditions.

View the 2024 grant recipients at The Park @ TLM located in the Sails Pavilion of the Convention Center or visit the Foundation booth located outside of The Park @ TLM.

TAP SNAP AT THE LIVER MEETING: CAPTURE THE MOMENT

Friday, November 15-Monday, November 18 from 12:00-2:00 PM

Strike a pose, choose your favorite backdrop, and snap away! Join AASLD Foundation for a fun and interactive experience with Tap Snap. Whether you're looking to capture memories with colleagues, share a laugh with new friends, or create a unique keepsake from your time at the event, Tap Snap has you covered. Don't miss this chance to take home a personalized memento from an unforgettable 75th The Liver Meeting. Donations appreciated!



CLUB 1950: SHAPING THE FUTURE OF HEPATOLOGY

Honoring AASLD's founding year, 1950, Club 1950 is a society of visionaries, trailblazers, and innovators who contribute \$1,950 annually. Starting Friday, Club 1950 members can join special events, including exclusive access to the Marriott Marquis Clubhouse for a full breakfast and General Session Clubseats.

All 2024 donors at the \$1,950 level are considered "Founding Members." View Club 1950 founders online now.



VIP DONOR* ACCESS AT THE LIVER MEETING

We are thrilled to recognize VIP Donors who have generously contributed \$500 or more to support the mission of AASLD Foundation. As a token of our appreciation, contributors enjoy exclusive access to the VIP Donor Lounge. If you like to give at the \$500+ level, ask us how at the Foundation Booth located outside The Park @ TLM.

**Exclusive to donors who made a gift of \$500+ in 2024 or by special invitation.*

THE 75TH ANNUAL LIVER MEETING PROGRAM



DOWNLOAD TLM'S MOBILE APP

For the most up-to-date information, download the TLM mobile app.

BEACON TECHNOLOGY

AASLD is using event badge beacons to replace badge scanning. AASLD will match the beacon with your attendee ID to track sessions you attend, which will aggregate beacon data to gauge overall interest in content. Data captured will be used to determine traffic patterns, room capacities, and inform future event programming of The Liver Meeting®. All attendee data is confidential. No data or information will be distributed or shared externally by AASLD or the vendor (TurnoutNow). The data will be deleted 30 days after The Liver Meeting®, and no other third parties will have access to it.

Attendees may request a badge without beacon technology. Visit the Registration Help Desk for assistance.

For more information on beacon technology, including how AASLD will utilize the data in real-time and in the future, visit The Liver Meeting website or registration desk on-site.



PROGRAMMING

FRIDAY • NOVEMBER 15

7:00–8:00 AM

 Social & Other Events

AASLD Foundation Emerging Liver APP Welcome Breakfast

Convention Center: Room 23

 Social & Other Events

AASLD Foundation Emerging Liver Scholars Breakfast

Convention Center: Room 24

8:00–9:30 AM

 Patient Programming

Moving Forward Together—Gaining Momentum in Patient–Provider Partnership

Convention Center: Room 11

This session will focus on the importance of patients and providers working together in partnership in the management of liver disease care. It will highlight ways in which patient-centered care can be created, how outreach can aid in improving patient access to care, and how patients can make a positive impact as advocates for liver disease care.

8:00 AM–5:00 PM

 Posters Session

Friday Poster Presentations

Convention Center: Hall C, Poster Hall

Friday's poster hall will feature:

- Acute on Chronic Liver Failure
- Hepatitis B, C, and Other Infections
- MASLD/MASH: Experimental–Basic and Clinical
- Vascular Liver Disease, Hemostasis and Thrombosis

Each poster session is categorized by topic and marked with a corresponding color for easy identification in the hall.

Poster presentations take place from 1:00–2:00 PM.

8:00 AM–5:30 PM

 Course

AASLD/ILTS Course, Parts 1–4

Expanding the Donor Pool

Convention Center: Ballroom 6C

This course will discuss advances in basic, translational, and clinical progress in liver transplantation. This timely program explores the most recent data in machine perfusion, transplant oncology, and strategies to increase access and equity to help update hepatologists on the contemporary and next stages in liver transplantation.

Part 1 (8:00–9:30 AM): Expanding the Donor Pool

Part 2 (11:00 AM–12:30 PM): Living Donor Liver Transplantation

Part 3 (2:00–3:30 PM): Hot Topics in Liver Transplantation

Part 4 (4:00–5:30 PM): MASLD and Liver Transplantation

8:00 AM–5:30 PM

 Course**Basic Science Symposium: Metabolic Landscape and Networks in Hepatobiliary Malignancies, Parts 1-4**

Metabolic Rewiring in Liver Cancer Cells

Convention Center: Ballroom 6A

This basic science symposium delves into the intricate interplay between metabolism and liver cancer. The program brings together leading experts, researchers, and scientists from various fields to explore cutting-edge developments in the understanding of how metabolic processes impact the development and progression of liver malignancies. The session includes presentations on metabolic reprogramming, metabolic competition between cancer cells and cells of the tumor microenvironment, immunometabolism, metabolic plasticity, and therapeutic opportunities targeting liver cancer metabolism. Growing awareness of the significance and prevalence of these mechanisms is leading to a deeper understanding of their involvement in tumor initiation and advancement. This understanding, in turn, is guiding basic and translational liver cancer research to identify metabolic vulnerabilities of liver cancers that might be exploited as therapeutic strategies.

Part 1 (8:00-9:30 AM): Metabolic Rewiring in Liver Cancer**Part 2 (11:00 AM-12:30 PM): Metabolic Vulnerabilities: Unraveling the Role of Mutations in Cancer****Part 3 (2:00-3:30 PM): Metabolic Interactions in the Tumor Microenvironment****Part 4 (4:00-5:30 PM): Metabolic Landscape and Networks in Hepatobiliary Malignancies** Course**Postgraduate Course, Parts 1-4: The Future Is Here—Practicing Hepatology in 2024** **Convention Center: Hall A: General Session**

With rapid advancements in digital health, big data, and artificial intelligence, the practice of hepatology is undergoing a transformative evolution. This four-session course provides comprehensive updates on crucially important diagnostics and therapeutics as they relate to persons with liver disease, with a focus on innovation and changing paradigms. Each session is practical and interactive, featuring four lectures followed by a question-and-answer discussion with the panel.

Session 1 (8:00–9:30 AM): A Day in the Life of the Modern Hepatologist—Steatotic Liver Diseases

This session addresses the most common liver diseases: metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD). Speakers address how to risk-stratify persons with MASLD using modern techniques available now or in the future. Presenters also discuss practical approaches to MASLD treatment, including both approved and pipeline therapeutics, along with novel treatments for obesity, including pharmaceutical, surgical, and endoscopic interventions. The changing role of hepatology clinicians and practical approaches for the treatment of alcohol use disorders are also explored.

Session 2 (11:00 AM–12:30 PM): Liver Cancers—New Solutions for Old Problems

Primary liver cancer remains one of the most lethal cancers worldwide. However, new hope arises from novel methods for risk stratification and treatment. This session reviews novel methods for risk stratification and surveillance, including electronic health record (EHR) risk stratification, novel imaging biomarkers, and new imaging modalities. Evolving paradigms for cholangiocarcinoma are addressed along with new treatments for HCC and the role of hepatology specialists in systemic therapy.

Session 3 (2:00–3:30 PM): Updates for the Liver Clinic in 2024

This session covers new developments in hereditary liver diseases, pediatric liver diseases, autoimmune liver diseases, and viral hepatitis. Topics addressed include new developments in Wilson disease, hemochromatosis, and alpha-1 antitrypsin deficiency; pediatric liver diseases updates; new developments in autoimmune liver diseases; and future directions for HBV/HDV coinfection therapy.

8:00 AM–5:30 PM

Session 4 (4:00–5:30 PM): Paradigm Shifts in Hepatology

Focusing on paradigm shifts in the care of persons with liver disease, this session explores the use of digital information to improve health disparities, changing approaches to portal hypertension treatment, and new technological advances to enhance the organ donor pool. The session concludes with a keynote lecture addressing how to harness the potential of our digital future.

11:00 AM–12:30 PM

 Patient Programming

Lifestyle Management of MASLD: Challenges and Opportunities

Convention Center: Room 11

This session features content about lifestyle interventions to empower patients to manage their MASLD.

12:30–2:00 PM

 Satellite Symposium

Updates in the Patient Journey: Autoimmune Hepatitis and Primary Sclerosing Cholangitis

Supported by *Perspectum Ltd.*
Organized by *HealthProMatch*

Convention Center, Ballroom 20A

This is an update on autoimmune liver disease, in particular AIH and PSC. There is a focus on the current evidence base around precision markers and NITs in diagnosing, monitoring, and prognosticating autoimmune disease and new treatments on the horizon. Finally, we explore how patient advocate groups can help inform PROMS and approaches to research.

Maximum 1.5 AMA PRA Category 1 Credits™

For more information and to register, visit:
healthpromatch.com/cme-event-nov-15/

 Satellite Symposium

Timing Is Everything: Optimizing Diagnosis and Personalized Treatment With First-Line Immunotherapy Plus Chemotherapy in Advanced Biliary Tract Cancer

Supported by *AstraZeneca, Inc.*
Organized by *Answers in CME*

Convention Center, Ballroom 20D

Two leading experts in biliary tract cancer—an oncologist and a hepatologist—will share best practices for early diagnosis and first-line treatment of advanced BTC with immunotherapy plus chemotherapy combinations, including multidisciplinary strategies to enhance patient quality of life on and off treatment.

Maximum of 1.0 AMA PRA Category 1 Credit(s)™

For more information and to register, visit:
answersincme.com/93641753

 Social & Other Events

AASLD Foundation Awardee Networking Luncheon 

Convention Center: Room 23

 Social & Other Events

AASLD Foundation Researcher Showcase Luncheon 

Convention Center: Room 24

12:30–2:00 PM

 Satellite Symposium

Primary Biliary Cholangitis: Real-World Outcomes in Context

Supported by Intercept Pharmaceuticals, Inc.
Organized by Medscape Education

Convention Center, Ballroom 20BC

This activity seeks to empower clinicians to effectively manage their patients with primary biliary cholangitis (PBC) and improve their outcomes. By enhancing your competence in monitoring disease activity and progression, identifying when there is a need for second-line therapy, and individualizing treatment for your patients, you will be better able to address delays in initiating appropriate therapy. Additionally, by providing real-world evidence on clinical outcomes beyond biomarkers and liver enzymes, such as decompensation, transplantation, and mortality, you will be better equipped to make more informed decisions about second-line therapy options.

1.25 CME and 1.25 Nursing Credits

For more information and to register, visit:
na.eventscloud.com/ereg/newreg.php?eventid=815748&

2:00–3:30 PM

 Patient Programming

HCV Elimination: Past, Present, and Future, 2013, 2024, and 2030

Convention Center: Room 11

Ten years after HCV treatment, second-generation DAAs broke the warehouse. Where are we now? What have we learned? And can we actually end hepatitis C by 2030? This session discusses different approaches to elimination around the country, in the past, present, and future.

2:00–5:30 PM

 Course

Obesity Medicine Course, Part 1-2

Convention Center: Ballroom 6F

This session, programmed in partnership with the Obesity Medicine Association, focuses on providing a foundational understanding of obesity as a disease and equips health care professionals with essential tools for the evaluation and diagnosis of adult and pediatric persons with obesity. The course delves into the basic concepts defining obesity and its pathophysiology. Presenters explore the four pillars of obesity treatment, i.e., nutrition therapy, physical activity, behavior modification, and medical management.

Note: Continuing education credits earned at this session count as group 2 credits toward the American Board of Obesity Medicine qualifications for certification via the CME pathway.


Part 1 (2:00–3:30 PM): Obesity Fundamentals

This session focuses on providing a foundational understanding of obesity as a disease and equips health care professionals with essential tools for the evaluation and diagnosis of adult and pediatric persons with obesity. The course delves into the basic concepts defining obesity and its pathophysiology. Presenters explore the 4 pillars of obesity treatment, i.e., nutrition therapy, physical activity, behavior modification, and medical management.

Part 2 (4:00–5:30 PM): Practical Approaches to Obesity Treatment: Strategies and Tools

This session builds on the foundational knowledge acquired in part 1 of the obesity medicine course and focuses on practical strategies for treating adult and pediatric persons with obesity. Speakers present valuable tools to develop effective treatment plans for persons affected by obesity. The session also addresses how to ethically—and in a non-stigmatizing manner—evaluate persons for obesity and related diseases.

Note: Continuing education credits earned at this session count as group 2 credits toward the American Board of Obesity Medicine qualifications for certification via the CME pathway.



DOWNLOAD TLM'S MOBILE APP

For the most up-to-date information,
download the TLM mobile app.

4:00–5:30 PM

 Patient Programming

Future Treatments, Trials, and Fatigue: Autoimmune in Focus

Convention Center: Room 11

This session will focus on what patients can expect of future treatment and trials in autoimmune liver diseases, symptom management (especially for fatigue), and a selection of research in these areas of interest to the patient community.

5:00–6:00 PM

 Social & Other Events

CLUB 1950 Welcome Hour 

Convention Center: VIP Donor Lounge

Open to all Club 1950 members. If you are interested in joining, visit the Foundation Booth located outside The Park @ TLM.

5:30–6:30 PM

 Social & Other Events

SIG Meet Ups–Day 1

Convention Center: Sails Pavilion, The Park @ TLM
Meet up #1-5

Join one of our Special Interest Group meet ups to connect with professionals who share your specific research and clinical interests. These social opportunities offer a platform for in-depth discussions and potential collaborations. The SIGs meeting at this time are listed below:

- Hepatotoxicity-Meet up #1
- Hepatitis B-Meet up #2
- Cholestatic and Autoimmune Liver Diseases (CALD)-Meet up #3
- Liver Fibrosis-Meet up #4
- Pediatric Liver Disorders (PLD)-Meet up #5

6:00–7:30 PM

 Social & Other Events

Distinguished Awards and Awards and Honors Ceremony

Convention Center: Hall A: General Session

7:30–9:30 PM

 Social & Other Events

Awards & Honors Reception 

 Satellite Symposium

Challenging Cases in Navigating Diagnostic Complexities and Strategies for Improved Management of Adults With Cholestatic Liver Diseases

Supported by Ipsen
Organized by Medscape Education

Marriott Marquis: Grand Ballroom 125 (Lobby Level)

There are delays in diagnosing, initiating treatment, and appropriately advancing therapy for adult patients with cholestatic liver diseases such as primary biliary cholangitis (PBC) and progressive familial intrahepatic cholestasis (PFIC). This case-based symposium will present key concepts, current evidence, and best practices for the early diagnosis and management of cholestatic liver diseases in adult patients.

Maximum of 1.50 AMA PRA Category 1 Credit

For more information and to register, visit:
www.medscape.org/symposium/cholestatic-liver

7:00–7:45 AM

Meet the Expert

MTE #1: Fontan-Associated Liver Disease: Management and Treatment

Convention Center: Room 33A

Fontan-associated liver disease (FALD) is a universal complication of patients with Fontan physiology with increasing clinical relevance. The optimal management of FALD, including screening for complications such as portal hypertension and HCC, remains poorly defined. Additionally, the role of transplantation (heart-only versus combined liver-heart) is complex. Experts in this session discuss both the medical and surgical complexities of FALD and outline opportunities for future collaborative efforts.

Meet the Expert

MTE #2: Hepatotoxicity in Drug Development: A Regulatory Perspective

Convention Center: Room 33B

The speakers address assessment of hepatotoxicity in clinical trials from the perspective of the US Food and Drug Administration (FDA). As clinical studies and trials are generally powered for efficacy but not safety, monitoring for hepatic safety and adjudicating hepatic safety events are a mixture of art and science. Two experts with extensive knowledge regarding clinical drug hepatotoxicity discuss monitoring and adjudication approaches, and how the FDA evaluates for liver safety signals in new drug marketing applications.

Meet the Expert

MTE #3: Hepatitis C Virus and Coinfections with Other Types of Viral Hepatitis

Convention Center: Room 33C

Experts discuss how to diagnose, treat, and prevent coinfections with HAV, HBV, HDV, HEV, and HIV in persons with acute or chronic HCV infection. Topics include clinical and laboratory assessment of HCV-infected persons with other types of viral hepatitis; treatment and follow-up strategies regarding coinfections with HAV, HBV, HDV, and/or HEV among HCV-infected persons; and prevention and consequences of coinfections among HCV-infected persons.

Meet the Expert

MTE #4: Cardiovascular Risk Assessment in Liver Transplant Candidates

Convention Center: Room 28E

Experts present information about recent advances in cardiovascular risk assessment and the burden of post-transplant major adverse cardiac events after liver transplant. Topics include the role of nuclear medicine positron emission tomography (NMPET) and computed tomography angiography (CTA) in cardiovascular risk stratification prior to liver transplant, and common cardiovascular complications post-transplant, including management approaches.

Meet the Expert

MTE #5: Liver-Organ Crosstalk

Convention Center: Room 30E

Experts discuss crosstalk between the liver and various organs in liver health and disease. Presenters highlight crosstalk involving the gut-liver axis and the muscle-liver axis in the context of liver disease.

Meet the Expert

MTE #6: Developing an Integrated Hepatology and Addiction Care Program for Hospitalized Patients With Alcohol Use Disorder: Improving Alcohol- and Liver-Related Outcomes

Convention Center: Room 31A

Morbidity and mortality due to alcohol-associated liver disease (ALD) will rise substantially over the next two decades. While multiple factors contribute to this trend, two deficiencies are clear: (1) persons with ALD are diagnosed at a late stage in their disease course, and (2) a minority of persons with ALD receive formal therapy for their alcohol use disorder (AUD). Implementation of a hepatology-led, inpatient alcohol service that consists of hepatology and addiction medicine specialists can effectively address these gaps. By evaluating patients without a history of liver disease or signs of active liver disease, this type of inpatient consultation can educate hospitalized AUD patients about liver disease; provide evaluation for the presence of subclinical advanced ALD; promote formal AUD therapy; and encourage/arrange follow-up in a multidisciplinary outpatient clinic. Speakers provide information on implementation strategies, outcome data, and strategies to improve AUD treatment uptake in persons at high risk for developing advanced (decompensated) liver disease.

7:00–7:45 AM

 Meet the Expert

MTE #7: Biomarker Discovery in Identifying At-Risk Metabolic Dysfunction-Associated Steatohepatitis Patients: A Bench Overview 

Convention Center: Room 31B

In this scientific session, experts educate attendees regarding the application of various omics technologies in the diagnosis and staging of metabolic dysfunction-associated steatohepatitis (MASH). Presenters focus on metabolomics, covering principles, biomarkers, and research techniques. Experts also dive into proteomics, exploring protein profiles and methodologies. Faculty highlight the role of microRNA and extracellular vesicles, emphasizing their significance and research methods. The session aims to impart insights into how these omics approaches contribute to a better understanding of MASH diagnosis and staging.

8:00 AM–5:00 PM

 Posters Session

Saturday Posters

Convention Center: Hall C, Poster Hall

Saturday’s poster hall will feature:

- Advanced Practice Providers
- Gut Liver Axis and Microbiome
- Health Disparities/Health Equity Research
- Hepatotoxicity
- Inflammation and Immunobiology
- Liver Transplantation and Liver Surgery
- MASLD/MASH: Diagnostics and Biomarkers and Epidemiology and Natural History

Each poster session is categorized by topic and marked with a corresponding color for easy identification in the hall.

Poster presentations take place from 1:00–2:00 PM.

8:00–9:30 AM

 Lecture

New Approaches to Chronic Hepatitis B in 2024 and Beyond

Convention Center: Room 29

This session provides an updated perspective on the evolving landscape of HBV management. With the advent of quantitative surface antigen testing now available globally, there is a significant shift in the ability to predict functional cures and establish potential stopping rules. This advancement offers hope in moving away from the notion of lifelong treatment and toward achieving functional cures. Program topics include: (1) simplification of HBV screening and treatment approaches; (2) the importance of universal access to birth-dose HBV vaccination; (3) the role of adopting a “test all, vaccinate all, and treat all” approach in the context of HBV elimination; (4) new data on tenofovir alafenamide safety and efficacy; (5) the efficacy of hepatitis B immunoglobulin-free strategies in infants born to highly viremic mothers who undergo antiviral prophylaxis; (6) expanding indications for treating mothers with HBeAg infection and the potential positive impact on global HBV control efforts; and (7) an updated global map detailing countries with mandated birth-dose HBV vaccines to aid in understanding regional disparities and inform targeted interventions. This comprehensive update aims to equip liver specialists, primary care clinicians, advanced practice providers, pharmacists, and gastroenterologists with the latest insights and strategies in HBV management. Staying informed and proactive enables all stakeholders to work collectively toward reducing the burden of HBV and, ultimately, achieving HBV elimination goals.

 Lecture

Caring for Kidneys Before and After Liver Transplantation

Ballroom 6F

The session focuses on the diagnosis and management of acute kidney injury in liver transplant candidates. Speakers focus on understanding the indications, patient selection, and outcomes of simultaneous liver-kidney transplant versus the safety net pathway and protecting kidneys after liver transplant.

8:00–9:30 AM

 Lecture

Cholestatic and Genetic Liver Diseases: Management Across the Lifespan, Part 1

Cholestatic Liver Diseases of Genetic Etiology: Presentation and Management

Convention Center: Room 28ABCD

Major advances have been made over the past decade in the genetic diagnosis and management of cholestatic liver disease in childhood. Adult hepatologists are now caring for increasing numbers of these patients who are receiving new medications, including ileal bile acid transporter (IBAT) inhibitors and the highly effective cystic fibrosis transmembrane regulator (CFTR) modulators. Ongoing clinical trials are also evaluating gene-based therapy for some of these diseases. Emerging data suggest that these novel therapies may favorably alter the natural history of cholestatic and genetic liver diseases. Part 1 of the cholestatic and genetic liver disease program specifically addresses cholestatic liver diseases of genetic etiology, including Alagille syndrome and progressive familial intrahepatic cholestasis.

 Workshop

Comprehensive Symptom Assessment and Management in Adults with Cirrhosis

Convention Center: Ballroom 6E

Speakers provide an in-depth description of symptoms experienced by persons with cirrhosis, many of which have dramatic effects on quality of life. Geared toward a clinician audience, presenters review pharmacologic and nonpharmacologic approaches to symptom management, evidence supporting specific treatment models, and practical advice that incorporates caregivers. Two case review sessions incorporate concepts presented in the lectures.

 Lecture

Mechanism-Based Therapies for the Treatment of Portal Hypertension

Convention Center: Ballroom 6A

Organized by the portal hypertension SIG, this session provides an update on new therapies based on the mechanisms of portal hypertension and chronic liver disease, with special emphasis on current knowledge regarding relevant pathophysiology, new preclinical and clinical data, and controversies in the field.

 Lecture

Metabolic Dysfunction–Associated Steatotic Liver Disease, Alcohol-Associated Liver Disease, and MetALD: Beyond the Nomenclature, Part 1

Epidemiology and Etiology

Convention Center: Ballroom 6B

Presenters in this two-part session dissect the intricate relationship between metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and the overlapping entity MetALD. Renowned experts explore these entities in terms of epidemiology, etiology, clinical diagnostics, and therapeutic approaches. Presenters delve into whether these conditions are distinct, overlapping, or part of a disease continuum by scrutinizing molecular, histologic, and epidemiologic evidence, and discuss future directions in screening, stratification, and drug development. Join this session to: (1) gain insights into the nuances that differentiate MASLD, ALD, and MetALD and the evidence supporting a spectrum or continuum of disease; (2) expand knowledge to apply advanced diagnostic tools effectively in clinical practice; (3) hone diagnostic and therapeutic strategies; and (4) develop a deeper understanding of the treatment landscape, unmet needs, and future directions in therapy and research for these liver diseases.

 Patient Programming

Patient Navigation of the Health Care System

Convention Center: Room 11

This session, developed by the Patient Advisory Group, will focus on helping patients and doctors navigate the full healthcare system together: diagnosis, barriers to care and opportunities, an exploration of advancing illness and end-stage liver disease, and transplantation.

 Lecture

Treating Liver Fibrosis in 2025: Prime Time or Are We Still in the Commercial Break?

Convention Center: Ballroom 6C

This program reviews recent updates in the rapidly evolving area of liver fibrosis treatment. Topics addressed by the expert presenters include an overview of the different therapeutic targets from metabolism to matrix; the goal of reversing rather than halting liver fibrosis; restoration of liver function in addition to antifibrogenic treatment and novel concepts that link the two; and personalized and combination therapy with a specific focus on metabolism.

8:00–9:30 AM



Surgical Advances in Hepatocellular Carcinoma: Optimizing Patients for Resection and Transplant

Convention Center: Ballroom 6D

This liver cancer SIG program addresses the rapidly evolving surgical treatment options for HCC, including resection and liver transplantation, which are making more patients with intermediate or even advanced-stage disease potentially eligible for curative therapy. This session highlights the changing landscape of surgical options for HCC, including identification and optimization of potential candidates for resection or transplant, advances in surgical techniques, the risk-benefit ratio of liver transplantation, and access to liver transplantation.

9:45–10:45 AM

Special Interest Group (SIGs) Business Meetings

- **ALD**
Convention Center: Ballroom 6B
- **Hepatitis B**
Convention Center: Room 29
- **Liver Cancer**
Convention Center: Ballroom 6D
- **Liver Fibrosis**
Convention Center: Ballroom 6C
- **Liver Transplantation**
Convention Center: Ballroom 6F
- **Pediatric Liver Disease**
Convention Center: Room 28ABCD
- **Portal Hypertension**
Convention Center: Ballroom 6A
- **Public Health**
Convention Center: Ballroom 6E

The AASLD SIG Business Meetings at TLM offer members of the Special Interest Groups a chance to connect with the steering committee and discuss pertinent initiatives and programming.

Community Conversations

Healthy Liver, Healthy Lives

Convention Center: Room 1

In this Community Conversations program, the North American launch of the Healthy Liver, Healthy Lives global coalition, founded by AASLD, ALEH, APASL and EASL is explained. With a focus on identifying opportunities, challenges and the future directions for tackling MASLD in the USA.

Community Conversations

What We Wish We Knew About Research and Publication

Convention Center: Room 24

Organized jointly by AASLD’s Journal Editors, presenters in this Community Conversations session discuss how to make journal manuscripts stand out to both editors and readers in the digital age. Topics include how to design a clinical research study, how to design a basic science study, the life cycle of a manuscript submission, and getting the most out of being a peer reviewer.

Community Conversations

Hepatology Associates as Leaders in HCV Elimination Programs

Convention Center: Room 23

In this Community Conversations program, a multidisciplinary panel of hepatology associates—nurse practitioners, physician assistants, registered nurses, pharmacists, etc.—discuss models in which associates are an integral part of the overall strategy for HCV elimination.

Social & Other Events

Diversity Meet Up

Supported by Madrigal Pharmaceuticals

Convention Center: The Park @ TLM: Meet Up #6

Join AASLD’s Diversity, Equity and Inclusion committees for this special social networking meet-up in The Park @ TLM. Meet and engage with other attendees interested in diversity and inclusion issues.

11:00 AM–12:30 PM

Lecture

Approaching Difficult Conversations with Seriously Ill Patients with Liver Disease and Their Families: Part 1

Convention Center: Ballroom 6E

In this session, speakers model strategies for approaching difficult conversations with seriously ill persons with liver disease and their family/caregivers. A case of a patient with alcohol-associated hepatitis who deteriorated during their hospitalization is presented. Modules review key phrases that can help clinicians promote illness understanding for patients and families; cultivate strong prognostic awareness; and respond to emotions effectively when communicating serious news. Participants have the opportunity to practice a core set of communication skills in small breakout sessions; these communication strategies help support care that is both high quality and patient centered when approaching the end of life.

Lecture

Build Bridges, Not Walls: Optimizing Liver Transplant Access and Care for People With Minoritized Identities

Convention Center: Room 28ABCD

Organized jointly by the AASLD LGBTQ Task Force and the Diversity Committee, this session focuses on the unique challenges faced by people in different minoritized groups, including Black/African American persons, Hispanic/Latina/Latino/Latinx persons, Native peoples, and sexual and gender minoritized (SGM) persons, within the realm of liver transplantation. Through presentations and dynamic panel discussions, the faculty aim to foster a comprehensive understanding of cultural nuances affecting transplant access and outcomes. The panelists present approaches that have been employed at their institutions to optimize access and care for solid organ transplants in different minoritized groups. The faculty further discuss societal and healthy policy adjustments required to drive meaningful change in the landscape of liver transplantation to ensure equitable access to quality transplant care for persons with minoritized identities. The program objectives include raising awareness and understanding, providing information to aid in the development of culturally sensitive strategies, and promoting collaborative solutions and advocacy among health care professionals, researchers, and other stakeholders.

Patient Programming

Adolescent Perspective: Diagnosis and Transition to Adult Care

Convention Center: Room 11

A discussion regarding the diagnosis of new disease in the unique adolescent patient population, including the transition of care from pediatric to adult providers.

Community Conversations

FDA Corner

Convention Center: Ballroom 6B

The purpose of this forum is to provide attendees insight into how the Division of Hepatology and Nutrition executes its regulatory mission to facilitate development of safe and effective products to treat non-viral liver disease. This session will focus on how new legislation may impact drug development for non-viral liver diseases, as well as major regulatory events that occurred within the division from September 1, 2023–August 31, 2024.

Lecture

Stemming the Rising Tide of New Viral Hepatitis Infections Globally

Convention Center: Room 29

Prevention of new infections is key to achieving the goal of global HBV and HCV elimination. Experts in this session discuss HBV and HCV epidemiology; challenges and potential solutions to reducing infections globally; and the respective roles of policy, harm reduction, improved diagnostics, and innovation in treatment/vaccination to address the key pillar of infection prevention in the overall approach to achieve HBV and HCV elimination.

11:00 AM–12:30 PM



Workshop

Surgery and Liver Transplantation Workshop, Part 1

How to Solve Disparities in Access to Liver Transplantation

Convention Center: Ballroom 6F

Speakers in this workshop provide an overview of different disparities involved in gaining access to liver transplantation and successful interventions that have ameliorated access disparities. Presenters also provide instruction regarding how to successfully implement specific programs to promote equity and justice in liver transplantation.



Lecture

What's New in Hepatocellular Carcinoma Screening and Prevention?

Convention Center: Ballroom 6D

This International Liver Cancer Association and American Association for the Study of Liver Diseases joint education session reviews the current status and highlights existing opportunities for improvements in HCC risk assessment, surveillance, and prevention. Although semiannual HCC surveillance can promote early HCC detection, adherence remains low and ultrasound misses many early-stage cancers. Given that prognosis after HCC diagnosis remains poor, prevention is paramount. Topics addressed in this program include: (1) emerging concepts in prevention, ranging from proven strategies (e.g., viral hepatitis treatment) to proposed strategies (aspirin, statins, etc.); (2) limitations of ultrasound-based HCC surveillance and novel surveillance strategies, including biomarkers and imaging methods (e.g., abbreviated MRI); (3) precision surveillance that combines the two aforementioned concepts, an approach recently endorsed by the European Association for the Study of the Liver; and (4) subsequent steps in the cancer care continuum, including recall after positive surveillance tests and linkage to care, including in rural areas.



Lecture

The Best of the Liver Fellow Network

Convention Center: Ballroom 6C

This session highlights the offerings of the Liver Fellow Network (LFN). Presentations feature impactful posts by content creators from the LFN core series. The Evidence Corner highlights important or landmark articles and presents high-yield aspects of the referenced studies. The Why? Series explores the dogma of liver disease management using a combination of historical perspective, basic physiology, and clinical experiential knowledge. The companion Back to Basics series reviews hepatology fundamentals, highlighting basic physiology and inpatient and outpatient management of persons with liver disease. The Clinical Pearls series addresses common or nuanced clinical questions employing an evidence-based, practical approach. The Pathology Pearls series teaches liver pathology interpretation using cases paired with high-resolution images. Following each core series presentation, the program moderators and panelists lead discussions with the goals of critically appraising the highlighted literature (Evidence Corner and the Why? Series); and discussing challenges and pearls in the diagnosis and management of patients with liver disease (Clinical Pearls, Pathology Pearls, and Back to Basics).



Lecture

The Editors Cut: Clinical Studies

Convention Center: Ballroom 6A

Associate Editors from the journal HEPATOLOGY, Drs. Juan Abraldes, Jacqueline O'Leary, and Alina Allen, discuss the most notable, influential, cutting-edge, game-changing clinical research papers published in HEPATOLOGY and elsewhere during the past year. A panel discussion with HEPATOLOGY Editor-in-Chief Dr. Gregory Gores and HEPATOLOGY Deputy Editor Dr. Harmeet Malhi focuses on the clinical impact of selected papers and key challenges and opportunities in the field.

12:30–2:00 PM

 Satellite Symposium

Discussing Key Clinical Decisions in Managing Primary Biliary Cholangitis

Supported by Gilead Sciences, Inc.
Organized by Medscape Education

Convention Center, Ballroom 20BC

Therapy goals for primary biliary cholangitis (PBC) are increasingly individualized and aspire to rapidly achieve normalization of biochemical markers. At the same time, novel therapies are poised to change the PBC treatment landscape. Attend this interactive, case-based symposium to learn from expert faculty about novel emerging treatments that may offer patients improved outcomes in PBC. In addition, a patient advocate will join our faculty to relate her experience of living with PBC, the burden of symptoms and impact on quality of life, and how patients and clinicians can best work together to achieve treatment goals.

Maximum of 1.25 AMA PRA Category 1 Credit(s)

For more information and to register, visit:
medscape.org/sympo/pbc-debate

 Satellite Symposium

Rethinking MASH

Supported by Perspectum Ltd.
Organized by HealthProMatch

Convention Center, Room: Ballroom 20A

Since new nomenclature and novel treatments have been approved for MASH, there is a need for designing accurate pragmatic patient care pathways. This update focuses on the evidence base behind precision markers and non-invasive tests in diagnosing, monitoring, and prognosticating patients with or at risk of MASH. This symposium also explores the challenges of a holistic approach to MASH patients with competing comorbidities and multi-organ involvement as well as novel approaches involving lifestyle interventions.

Maximum of 1.5 AMA PRA Category 1 Credit(s)[™]

For more information and to register, visit:
healthpromatch.com/cme-event-nov-16/

 Satellite Symposium

In Pursuit of a Functional Cure for Hepatitis B: Monitoring Effectively, Optimizing Treatment, and Reducing the Risk of Complications

Supported by GSK
Organized by PVI, PeerView Institute for Medical Education

Convention Center, Ballroom 20D

Despite safe, effective vaccines and antiviral treatments, HBV infection remains a major health concern. In this event from PeerView, experts explore HBV serologic testing for monitoring disease, evidence-based treatment to achieve a functional cure, and monitoring approaches for treatment response, disease progression, and detection of liver fibrosis, cirrhosis, and HCC.

Maximum of 1.50 AMA PRA Category 1 Credits[™]

For more information and to register, visit:
PeerView.com/SanDiego-HepB-Live

12:45–1:30 PM

 Meet the Expert

MTE #8: Breaking Down Barriers to Care for Hepatocellular Carcinoma 

Convention Center: Room 33A

Faculty highlight successful interventions to improve access to care for vulnerable populations with HCC. The scope of access disparities, specific barriers encountered, solutions applied, and lessons learned are presented. Experts outline pathways to implementation and facilitate discussion of best practices.

 Meet the Expert

MTE #9: Cirrhotic Cardiomyopathy: Diagnosis and Clinical Relevance 

Convention Center: Room 33B

Experts in this session provide valuable insights regarding the diagnosis and clinical relevance of cirrhotic cardiomyopathy. Presenters focus on the evolving definitions of cirrhotic cardiomyopathy, mechanisms and risk factors for the condition, and the clinical consequences before and after liver transplantation.

 Meet the Expert

MTE #10: Therapies in the Pipeline for Primary Biliary Cholangitis 2024 

Convention Center: Room 33C

Experts in this interactive, small group discussion present the most up-to-date pipeline for drug development in primary biliary cholangitis (PBC). Speakers address the indications for second-line therapy in PBC; the proposed benefits of various drugs in development and differences in their expected mechanisms of action; and potential management algorithms, considering risks and benefits of each drug. This session provides attendees the opportunity to hold informal conversations with key thought leaders in the field.

 Meet the Expert

MTE #11: Distinct and Common Fibrotic Pathways in Metabolic Dysfunction-Associated Steatohepatitis Versus MetALD 

Convention Center: Room 28E

Speakers present the common and distinct pathways involved in hepatic stellate cell activation and fibrogenesis in metabolic dysfunction-associated steatohepatitis (MASH) and MetALD in relation to disease-specific therapeutic approaches.


 Meet the Expert

MTE #12: Establishing a Tumor Board: Best Practices 

Convention Center: Room 30E

Experts discuss best practices for the establishment of a multidisciplinary tumor board, including the unique roles of hepatology associates in this process.

 Meet the Expert

MTE #13: Transjugular Intrahepatic Portosystemic Shunt in Acute-on-Chronic Liver Failure Patients: Why and When? 

Convention Center: Room 31A

In this session, acute-on-chronic liver failure (ACLF) SIG members present cases of patients with severe portal hypertension and ACLF. Experts present the evidence supporting the management of acute and acute-on-chronic portal hypertension in the ACLF patient. The session concludes with a question-and-answer period with the experts and attendees.

 Meet the Expert

MTE #14: Prevention and Treatment of Hepatitis B in Children 

Convention Center: Room 31B

Recent advances in the prevention and treatment of hepatitis B in children have revolutionized health care. Presenters discuss improved vaccination strategies, including the introduction of combination vaccines, which have bolstered prevention efforts. Speakers also explain how novel antiviral therapies have enhanced treatment outcomes, reducing the risk of chronic infection and associated complications in pediatric patients.

1:00-2:00 PM

 Social & Other Events

AASLD Annual Business Meeting

Convention Center: Room 1

2:00-3:00 PM

 Lecture

Approaching Difficult Conversations with Seriously Ill Patients with Liver Disease and Their Families: Part 2

Convention Center: Ballroom 6E

In this session, speakers model strategies for approaching difficult conversations with seriously ill persons with liver disease and their family/caregivers. A case of a patient with alcohol-associated hepatitis who deteriorated during their hospitalization is presented. Modules review key phrases that can help clinicians promote illness understanding for patients and families; cultivate strong prognostic awareness; and respond to emotions effectively when communicating serious news. Participants have the opportunity to practice a core set of communication skills in small breakout sessions; these communication strategies help support care that is both high quality and patient centered when approaching the end of life.

2:00-3:30 PM

 Lecture

Bridging the Acute-on-Chronic Liver Failure Patient for Liver Transplantation: Pearls and Pitfalls

Convention Center: Ballroom 6A

In this session, the acute-on-chronic liver failure (ACLF) SIG presents a case of a critically ill patient with severe ACLF being evaluated for liver transplantation. The case serves as the springboard to discuss four distinct topics focusing on clinical patient management: (1) critical care strategies, (2) bridging therapies, (3) outcomes in patients considered for and transplanted for ACLF, and (4) the role of living donor liver transplantation. The session concludes with a case summary and panel discussion.

 Lecture

Cell-Molecule Circuitry of Hepatobiliary Repair

Convention Center: Ballroom 6D

In this session, panel members discuss recent advances in understanding the cellular and molecular basis of hepatobiliary repair. The concepts covered by thought leaders and content experts include the roles of various metabolic zones in the liver lobule in maintaining hepatic homeostasis, as well as in regeneration following injury or resection, and the balance of metabolic/synthetic function and proliferation during liver repair and what controls such balance. Presenters also address the concepts of hepatocyte to cholangiocyte reprogramming and vice versa (i.e., transdifferentiation) during specific chronic pathologies affecting cholangiocytes and hepatocytes, respectively. Finally, panelists review synthetic biology approaches, including the use of personalized hepatic organoids and gene editing for understanding rare and orphan liver diseases.

2:00–3:30 PM

 Lecture

Cholestatic and Genetic Liver Diseases: Management Across the Lifespan, Part 2
Channelopathy and Ciliopathy: Liver Manifestation and Therapeutic Advances

Convention Center: Room 28ABCD

Major advances have been made over the past decade in the genetic diagnosis and management of cholestatic liver disease in childhood. Adult hepatologists are now caring for increasing numbers of these patients who are receiving new medications, including ileal bile acid transporter (IBAT) inhibitors and the highly effective cystic fibrosis transmembrane regulator (CFTR) modulators. Ongoing clinical trials are also evaluating gene-based therapy for some of these diseases. Emerging data suggest that these novel therapies may favorably alter the natural history of cholestatic and genetic liver diseases. Part 2 of the cholestatic and genetic liver disease program specifically addresses cystic fibrosis-related liver disease presentation, management, and monitoring and polycystic liver disease associated with autosomal dominant polycystic kidney disease.

 Patient Programming

Hepatitis B—Improving Care by Addressing Stigma

Convention Center: Room 11

In this session developed by AASLD's Patient Advisory Group, we will examine the effects of stigma and discrimination on patient outcomes and review successful intervention in populations at risk for discrimination.

 Lecture

Hepatitis C Virus 2024: From Prevention to Management

Convention Center: Room 29

Experts review and discuss the most up-to-date information on rapid, point-of-care HCV diagnostic strategies; HCV vaccine development and its importance in achieving the goal of HCV elimination; and the management of special populations with chronic HCV infection, including difficult-to-treat or hard-to-reach persons.

 Lecture

Human Liver Organoids for Drug Efficacy and Toxicity: Promises and Pitfalls

Convention Center: Ballroom 6C

Human liver organoids are functional three-dimensional in vitro models of the liver that can serve as a novel platform to address diverse research questions related to drug-induced liver injury. Organoid models provide a more physiologic in vitro system to study hepatotoxicity compared to two-dimensional, traditional tissue culture. In addition, personalized approaches using patient organoids are powerful tools that hold the promise for improving patient outcomes. In this session, attendees learn about the unique aspects of these valuable research tools that can offer a personalized approach in medicine by recreating patient-specific organ models, and the role of organoids in drug development and testing toxicity from a regulatory perspective.



DOWNLOAD TLM'S MOBILE APP

For the most up-to-date information,
download the TLM mobile app.

2:00–3:30 PM

Lecture

Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol-Associated Liver Disease, and MetALD: Beyond the Nomenclature, Part 2

Clinical Diagnostics and Therapeutics

Convention Center: Ballroom 6B

Presenters in this two-part session dissect the intricate relationship between metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and the overlapping entity MetALD. Renowned experts explore these entities in terms of epidemiology, etiology, clinical diagnostics, and therapeutic approaches. Presenters delve into whether these conditions are distinct, overlapping, or part of a disease continuum by scrutinizing molecular, histologic, and epidemiologic evidence, and discuss future directions in screening, stratification, and drug development. Join this session to: (1) gain insights into the nuances that differentiate MASLD, ALD, and MetALD and the evidence supporting a spectrum or continuum of disease; (2) expand knowledge to apply advanced diagnostic tools effectively in clinical practice; (3) hone diagnostic and therapeutic strategies; and (4) develop a deeper understanding of the treatment landscape, unmet needs, and future directions in therapy and research for these liver diseases.

Workshop

Surgery and Liver Transplantation Workshop, Part 2

Convention Center: Ballroom 6F

This session provides an overview of the strategies and indications for liver transplantation. Additionally, it covers advances in medical and surgical treatments that can expand the donor pool for liver transplantation and provide better patient outcomes.

3:45–4:45 PM

Academic Debates

Academic Debate

Convention Center: Room 30ABCD

In this session, hepatology trainees and practicing hepatologists will tackle a controversial hepatology topic in a lively debate format. Debaters and audience members will grapple with opposing scientific, societal, individual, and financial viewpoints in considering this topic.

Community Conversations

Nuts and Bolts of Liver Allocation: Balancing Urgency and Survival Benefit

Convention Center: Room 1

This jointly organized program presented by the American Association for the Study of Liver Diseases and the American Society of Transplantation reviews current and future liver allocation policy with a focus on the principles of policy development to promote equity and emerging indications for liver transplantation.

Community Conversations

Pathologists Are from Mars, Hepatologists Are from Venus: How to Decode Pathology Reports to Solve Hepatology Diagnostic Puzzles

Convention Center: Room 24

Correct interpretation of pathology reports and demystifying some liver pathology terms and concepts are the focus of this Community Conversation. The session utilizes educational cases such as autoimmune hepatitis, overlap syndromes, and steatohepatitis with autoantibodies as a platform to promote interactive discussions. This program will encourage attendee questions and comments and focus not only on pathology but also on the utilization of pathology reports to facilitate diagnosis and further work-up. In addition to educational cases, the program includes some fun pictures/examples that illustrate the importance of clinicopathologic correlation in different clinical settings.

3:45–4:45 PM

 Community Conversations

Establishing Patient-Reported Outcomes in Pediatric Liver Transplantation

Convention Center: Room 23

Pediatric liver transplant (LT) recipients navigate a lifelong journey that includes continual monitoring and challenges. Research priorities and questions in LT have traditionally been provider driven. In this Community Conversation, speakers present and discuss recent efforts to establish novel partnerships between a learning health system dedicated to pediatric LT (Starzl Network for Excellence in Pediatric Transplantation) and a parent-led advocacy group (Transplant Families) that aims to prepare families and providers for collaborative, patient-centered outcomes research (PCOR).

 Special Interest Group (SIGs) Business Meetings

- **ACLF**
Convention Center: Ballroom 6A
- **Clinical Practice**
Convention Center: Ballroom 6E
- **Cholestatic Liver Disease**
Convention Center: Room 28ABCD
- **Hepatitis C**
Convention Center: Room 29
- **Hepatotoxicity**
Convention Center: Ballroom 6C
- **Liver Cell Biology**
Convention Center: Ballroom 6D
- **MASLD**
Convention Center: Room 6B

The AASLD SIG Business Meetings at TLM offer members of the Special Interest Groups a chance to connect with the steering committee and discuss pertinent initiatives and programming.

5:00–6:00 PM

 State of the Art (SOA)

President’s Welcome & President’s Choice Lecture: The Two Most Important Days: Finding Lasting Happiness and Purpose in Hepatology, a Look Back in the Rearview Mirror and a Glimpse Ahead

Convention Center: Hall A: General Session

The last 75 years have witnessed a number of landmark developments and discoveries in hepatology. These include the founding of the AASLD, the first successful liver transplantation, the awarding of the Nobel Prize for brilliant work on hepatitis B and hepatitis C, and the emergence of the dominant chronic liver disease globally, metabolic dysfunction-associated steatotic liver disease (MASLD). The big stories playing out now include artificial intelligence, the gut microbiome, CRISPR and gene editing, and messenger RNA. This presentation will reflect on the impressive growth in the field of hepatology and explore how hepatologists can eminently succeed, and even flourish, in the face of these rapid changes by incorporating grit and embracing the four tenets of happiness.

6:00–6:45 PM

 Social & Other Events

First-Time Attendee Reception

Convention Center: Member Lounge, Room 4

This reception offers a warm and inviting atmosphere where first-time attendees can meet fellow newcomers and AASLD social media ambassadors to learn how to make the most of their first TLM.

6:00–7:00 PM

 Social & Other Events

Leadership Giving Challenge Reception 

Convention Center: VIP Donor Lounge

6:00–7:30 PM

 Social & Other Events

Exhibit Hall Opening Reception

Supported by *Mirum Pharmaceuticals*

Convention Center: Exhibit Hall B

Kick off The Liver Meeting with an evening of mingling, refreshments, and a warm welcome from AASLD as you explore the Exhibit Hall. This casual gathering provides the opportunity to meet new colleagues and hear from industry leaders.

7:00–7:45 PM

 Social & Other Events

Trainee Reception Hosted by Liver Fellow Network

Convention Center: Member Lounge, Room 4

An exclusive event for early career professionals to connect with peers and leaders from the Liver Fellow Network. Engage in insightful conversations, share experiences, and build relationships that can help advance your career in hepatology.

7:30– 8:30 PM

 Social & Other Events

Pride Reception

Marriott Marquis: San Diego Ballroom A

Celebrate diversity and inclusion within the hepatology community at AASLD's Pride Reception, hosted by the LGBTQ Task Force. This event provides a supportive space for LGBTQ+ members and allies to connect, share experiences, and foster a welcoming environment for everyone.

7:30–9:30 PM

 Satellite Symposium

The Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care

Supported by *Boehringer Ingelheim Pharmaceuticals* and *Novo Nordisk, Inc.*

Organized by *Medtelligence*

Marriott Marquis: Grand Ballroom 125 (Lobby Level)

This symposium will provide practical, interactive discussions of cardiometabolic pathophysiologic pathways, early identification and risk stratification, advances in treatment monitoring for disease progression, and long-term medical management, including the role of incretin agonists.

Maximum of 1.5 AMA PRA Category 1 Credits™

For more information and to register, visit:

ReachMD.com/segment/26613

 Satellite Symposium

LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today and Tomorrow?

Supported by *AstraZeneca, Inc.*

Organized by *Physicians Education Resource*

Marriott Marquis: Grand Ballroom 346 (Lobby Level)

As the treatment landscape for hepatocellular carcinoma (HCC) continues to evolve, multidisciplinary, coordinated therapeutic intervention remains the cornerstone of care for these patients. Expert insights into treatment selection and collaborative decision-making are critical to informing and optimizing patient outcomes in resectable and unresectable disease.

This hybrid Liver Cancer Tumor Board® symposium will bring together renowned experts in the management of HCC. In this educational program, these experts will share clinical insights and advances in the management of HCC with novel neoadjuvant, adjuvant, and perioperative immunotherapy-based therapeutic strategies.

Maximum of 2.0 AMA PRA Category 1 Credits™

For more information and to register, visit:

gotoper.com/courses/liver-cancer-meeting

7:00–7:45 AM

 Meet the Expert

MTE #15: Inflammation and Immune Dysregulation in Pediatric Acute Liver Failure 

Convention Center: Room 33A

Pediatric acute liver failure (ALF) is a dynamic, life-threatening condition of disparate etiology. In a subset of patients, most commonly those with an indeterminant etiology, patients appear to have evidence of immune-mediated liver injury driven by untethered inflammatory responses. In this session, experts discuss the current understanding of the inflammatory and immune mechanisms driving pediatric ALF and efforts to better identify potential therapies to improve morbidity and mortality.

 Meet the Expert

MTE #16: Cannabis and Cannabidiol Hepatotoxicity 

Convention Center: Room 33B

Speakers discuss the data regarding hepatotoxicity from cannabis and cannabidiol compounds.

 Meet the Expert

MTE #17: Unique Aspects of Managing Hepatitis C Virus Infection in Persons with Cancer 

Convention Center: Room 33C

Experts discuss unique considerations related to HCV infection among persons with cancer. Topics include the rationale for HCV screening in persons with cancer, monitoring HCV-infected persons with cancer not receiving direct-acting antiviral (DAA) treatment, and timing and benefits of DAA therapy in relation to cancer treatment.

 Meet the Expert

MTE #18: Management of Hepatorenal Syndrome: Acute Kidney Injury in Liver Transplant Candidates 

Convention Center: Room 28E

Experts review the diagnosis, prognosis, and management of hepatorenal syndrome–acute kidney injury (HRS–AKI). Topics include the role of biomarkers in the diagnosis of HRS–AKI, and pharmacologic and nonpharmacologic treatment options in liver transplant candidates.

 Meet the Expert

MTE #19: Macrophage Dynamics and Function in Liver Disease 

Convention Center: Room 30E

Experts discuss the role and regulation of macrophages in liver pathophysiology. Presenters highlight macrophage subpopulations, recruitment, markers, and signaling as it relates to various liver diseases. Discussion focuses on how macrophage modulation may be useful as a predictive biomarker or a target for therapeutic interventions.

 Meet the Expert

MTE #20: Expanding the Frontiers for Liver Transplantation in Severe Alcohol-Associated Hepatitis 

Convention Center: Room 31A

The faculty for this session explore the latest criteria and considerations for selecting candidates for liver transplantation in the context of severe alcohol-associated hepatitis. Speakers delve into the prognostic factors that influence outcomes and discuss the potential and challenges of living donor liver transplantation as a treatment option.

7:00–7:45 AM

 Meet the Expert

MTE #21: Metabolic Dysfunction–Associated Steatotic Liver Disease in Asia

Convention Center: Room 31B

Experts explore the multifaceted landscape of metabolic dysfunction–associated steatotic liver disease (MASLD) in Asia, addressing regional epidemiology, risk factors, and clinical nuances to equip health care professionals and researchers with the knowledge needed to effectively address this growing public health concern. Presenters instruct participants to facilitate attainment of the expertise needed to identify and diagnose MASLD in Asian populations utilizing specific biomarkers and diagnostic tools. Experts explore advanced management and treatment approaches tailored to Asian patients with an emphasis on enhancing patient outcomes. Faculty also address the importance of culturally sensitive health care delivery to ensure effective engagement with diverse Asian communities affected by MASLD.

8:00–9:30 AM

 State of the Art (SOA)

Thomas E. Starzl SOA: Life After a Liver Transplant—Victories, Challenges, and Opportunities for More and Liver Transplant Plenary

Convention Center: Hall A: General Session

With advances in surgical techniques, multidisciplinary care, and immunosuppression, patient and graft survival continue to improve in liver transplantation. Excellent patient and graft survival have translated into an aging liver transplant recipient cohort that resembles a general chronic disease population. This session addresses the complexity of long-term care of liver transplant survivors, strategies to mitigate morbidity, and approaches to promote the long-term health and well-being of liver transplant recipients.

 Workshop

Transformative Impact of Artificial Intelligence on Basic Liver Research: From Predicting Protein Structure to Multimodal Data, Part 1

Convention Center: Room 29

This workshop addresses how AI is revolutionizing the life sciences in hepatology and increasingly permeating the world of basic science. AI tools can be used for experimental design and modeling. AlphaFold, a landmark AI tool developed to predict protein conformation, is informing the development of small molecule inhibitors for different conditions. Other AI applications in basic research include sequencing, imaging, and structural biology. AI is being used to integrate clinical and high-throughput omics data for personalized diagnostic predictions and promises to inform individualized therapeutic approaches.

 Parallel Session

MASLD and MASH—Natural History and Existing Therapy

Convention Center: Ballroom 6A

 Parallel Session

Hepatitis B—New Insights with Use of Approved Therapies

Convention Center: Ballroom 6B

 Parallel Session

Portal Hypertension and Other Complications of Cirrhosis—New Scientific Discoveries

Convention Center: Room 28ABCD

8:00–9:30 AM

 Patient Programming

Navigating the Challenges: Understanding and Managing Complications of Cirrhosis

Convention Center: Room 11

This session will provide a clear understanding of the common complications that can arise from cirrhosis, such as fluid accumulation in the abdomen (ascites), confusion or changes in brain function (hepatic encephalopathy), and internal bleeding. You will learn to recognize early signs of these complications and understand the importance of timely medical intervention. This session will provide practical guidance on lifestyle adjustments and self-care strategies to effectively manage and enhance your quality of life. Our aim is to empower you with the knowledge to navigate your health journey with cirrhosis.

 Workshop

Career Development Workshop

Convention Center: Room 24

This session focuses on topics of relevance to trainees and junior hepatology faculty for career development. Topics include a description of the Adult Transplant Hepatology Match process, a career in pediatric transplant hepatology, research options in hepatology, and career advancement and promotion, including essential knowledge and support needed from mentors and junior and senior faculty. There will be a dedicated opportunity for roundtable discussions among presenters and participants.

 Lecture

Global Perspectives on Hepatocellular Carcinoma

Convention Center: Ballroom 6D

This session will focus on global aspects of hepatocellular carcinoma, exploring the epidemiology, different risk factors and treatment approaches for hepatocellular carcinoma in various regions of the world. Leading experts from each region will present on specific aspects of HCC that are important globally and regionally.

 Course

Hepatology Associates Course, Part 1

Viral Hepatitis and Alcohol Use Disorder in the Liver Clinic Today

Convention Center: Ballroom 6F

The hepatology associates course aims to expand participants' knowledge and thereby improve patient outcomes. Topics include viral hepatitis, alcohol use disorder in the liver clinic, liver biopsy in clinical practice, current noninvasive testing for portal hypertension, diagnosis of liver lesions, and practical use of genetics in liver clinical practice.

 Course

North American Society For Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Course: Harnessing Research and Clinical Breakthroughs in the Care of Children With Liver Disease

Convention Center: Ballroom 6C

Targeted research and clinical trials have resulted in considerable progress in novel treatment strategies for liver disease. This session highlights innovations in both adult and pediatric hepatology that have the capacity to transform the care of pediatric patients with a spectrum of liver disease. Topics include: (1) the current landscape of ileal bile acid transporter (IBAT) inhibitors for the treatment of children with Alagille syndrome and progressive familial intrahepatic cholestasis, and investigation in other cholestatic liver diseases; (2) utilization of existing and novel therapies for cures or bridging to transplant in pediatric acute liver failure, including terlipressin, bioartificial liver systems, and hepatocyte and auxiliary transplant; (3) use of gene therapy in pediatric liver disease and the landscape for future innovations; (4) overview of current and future therapeutics for metabolic dysfunction-associated steatotic liver disease and applicability to young adults treated at pediatric centers; and (5) promising data on small interfering RNA therapy for alpha-1-antitrypsin disease and other applications.

8:00 AM–5:00 PM

Posters Session

Sunday Poster Presentations

Convention Center: Hall C, Poster Hall

Sunday's poster hall will feature:

- Alcohol-Associated Liver Diseases: Clinical and Experimental
- Health Services and Public Health Research
- Hepatobiliary Neoplasia
- Liver Fibrogenesis and Non-Parenchymal Cell Biology
- MASLD/MASH: Therapeutics-Approved/Available Agents and New Agents

Each poster session is categorized by topic and marked with a corresponding color for easy identification in the hall.

Poster presentations take place from 1:00–2:00 PM.

9:45–10:45 AM

Community Conversations

NIH Corner – NCI

Convention Center: Ballroom 6E

National Cancer Institute program staff will discuss current funding opportunities for basic and clinical research at the National Cancer Institute and take questions regarding the grant process and funding opportunities.

Community Conversations

Capacity Building and Advocacy to Achieve Hepatitis C Virus Elimination

Convention Center: Room 23

Presenters engage stakeholders, including persons with HCV, to discuss key evidence-based, capacity-building models for increasing access to HCV care and treatment along with important advocacy work needed to achieve HCV elimination. This session highlights telemedicine and pharmacy-led models of HCV care and important advocacy work still needed to expand HCV treatment access.

Community Conversations

Designing Clinical Trials for Alcohol-Associated Liver Disease

Convention Center: Room 1

This Community Conversation engages clinical researchers at all levels—from trainees to senior investigators—in discussions related to clinical trials involving alcohol-associated liver disease (ALD) and alcohol-associated hepatitis (AH). From design to implementation, this session highlights special considerations such as endpoint selection, development of novel biomarkers, novel clinical trial designs, emerging pharmacotherapies, alcohol consumption during clinical trials, and opportunities in ALD and combined metabolic dysfunction-associated and alcohol-associated liver disease (MetALD). Topics addressed include (1) selection of appropriate clinical and patient-reported endpoints that consider both clinical relevance and statistical rigor; (2) limitations of traditional biomarkers and emerging novel biomarkers relevant for monitoring and targeting such clinical and patient-reported endpoints; (3) outcomes specific to liver disease, alcohol use disorder (AUD), and the intersection of ALD and AUD; (4) practical guidance for initiating novel clinical trial designs, including assessment of the environment and necessary resources; (5) strategies to improve subject participation and retention; and (6) emerging interventions with potential for overlap in ALD and MetALD.

Community Conversations

Transplant Hepatology Fellowship and Beyond: Ask-Me-Anything Small Group

Convention Center: Room 24

This Community Conversation program offers a unique opportunity to realize the Liver Fellow Network's (LFN) goal of expanding nationwide near-peer mentorship with this face-to-face forum. The program consists of 10 small (10-person) groups led by a junior faculty member or transplant hepatology fellow fielding questions from trainees or aspiring hepatologists about clinical, academic, and research hepatology; navigating the job search and negotiation processes; career development; and work-life balance. Early career trainees to junior faculty members are invited to seize this opportunity to seek advice and near-peer mentorship regarding the exploration of transplant hepatology training or pursuit of aligned career opportunities.

9:45-10:45 AM

 Community Conversations**Wait Wait... Don't DILI!****Convention Center: Ballroom 6D**

Based loosely on themes from the NPR program Wait Wait... Don't Tell Me!, this engaging, informal, open-format session features three short speed data/graphical abstract style presentations on high-impact and emerging topics in hepatotoxicity. Hosted by members of the hepatotoxicity SIG committee and invited panelists, the moderator introduces each speaker with a limerick. Each brief presentation is followed by audience engagement and a question-and-answer period. Attendees receive ballots to complete with responses to the limericks. At the conclusion of the session, 10 winners will be awarded an exclusive Wait Wait... Don't DILI! limited-edition special prize.

 Social & Other Events**Global Societies Meet Up****Convention Center: The Park @ TLM: Meet Up #6**

This exciting event offers the unique opportunity to connect with liver disease leaders from around the world. Whether you're looking to expand your global network or discuss pressing topics in liver disease, this meet-up is the perfect setting to engage in meaningful conversation. This is your chance to exchange knowledge and ideas, globally!

10:00-10:45 AM

TLM Theater

Discover a Treatment Option that Is Available for Patients with NASH with Liver Fibrosis*Supported by Madrigal Pharmaceuticals, Inc.***Convention Center: Exhibit Hall B, TLM Theater 1**

Please join us for an engaging and highly anticipated educational panel presentation focusing on a treatment option for patients with NASH, including the clinical data.

TLM Theater

Key Considerations When Choosing a First-Line Treatment Option for Unresectable Hepatocellular Carcinoma*Supported by AstraZeneca, Inc.***Convention Center: Exhibit Hall B, TLM Theater 2**

This presentation will cover important factors in selecting a first-line treatment option for patients with unresectable hepatocellular carcinoma (HCC). It will explore the efficacy and safety from a clinical trial, including the latest evidence from recent analyses.

11:00 AM-12:30 PM

 State of the Art (SOA)**Hyman J. Zimmerman Hepatotoxicity SOA: Lipotoxicity in the Liver, and Clinical Plenary #1****Convention Center: Hall A: General Session**

Organs and tissues exhibit distinct features of structural organization at various scales to meet functional demands and adapt to challenges to maintain homeostasis and viability. However, detailed resolution of native intracellular molecular architecture and the relationship of molecular architectural formations to metabolic function remains poorly understood. This lecture features presentation of subcellular architecture at the nanoscale level in native liver tissue and reviews how these structures are regulated during both physiological responses and metabolic disease. Such nanoscale resolution observations are made possible by utilizing multiple imaging platforms, including enhanced focused ion beam scanning electron microscopy (FIB-SEM), followed by deep-learning-based image segmentation, combined with biochemical and physiological approaches. This line of inquiry demonstrates that hepatic subcellular molecular architecture is highly dynamic and regulated, integrated with the metabolic program of the cell, and critical for adaptive homeostasis in health and its disruption in disease.

 Parallel Session**Liver Transplantation and Liver Surgery- Current State of Disparities in Liver Transplant****Convention Center: Ballroom 6A**

11:00 AM-12:30 PM

 Parallel Session

Hepatobiliary Neoplasia—Early Detection and Prediction of Response

Convention Center: Ballroom 6B

 Parallel Session

Advances in Pediatric Liver Disease: Clinical

Convention Center: Ballroom 6C

 Parallel Session

Acute Liver Failure: Pathophysiology, Prognostication, and Management

Convention Center: Room 28ABCD

 Course

Hepatology Associates Course, Part 2

Diagnostic Tools in Liver Disease

Convention Center: Ballroom 6F

The hepatology associates course aims to expand participants' knowledge and thereby improve patient outcomes. Topics include viral hepatitis, alcohol use disorder in the liver clinic, liver biopsy in clinical practice, current noninvasive testing for portal hypertension, diagnosis of liver lesions, and practical use of genetics in liver clinical practice.

 Lecture

American Association for the Study of Liver Diseases (AASLD) and Latin American Association for the Study of the Liver (ALEH) Joint Symposium:

Challenges in Drug-Induced Liver Injury, a Tale of Two Continents

Convention Center: Ballroom 6D

The American Association for the Study of Liver Diseases and the Latin American Association for the Study of the Liver joint symposium focuses on the experiences of investigators in Latin America and the United States with hepatotoxicity due to drugs and herbal and dietary supplements (HDSs). The first part of the session focuses on the epidemiology, prevalence, and increasing incidence of hepatotoxicity due to HDSs. Given increasing HDS use and availability (including online), presenters stress the importance of learning about new compounds, trends in HDS use, and potential new toxins for all hepatologists and other health care professionals practicing in the field to be aware of. The second portion of the symposium focuses on drug-induced autoimmune-like hepatitis (DI-ALH), a clinical challenge in many cases of hepatotoxicity. In this segment, experts discuss the presentation, diagnosis, and management of DI-ALH, and how to differentiate it from de novo autoimmune hepatitis.

 Patient Programming

Palliative Care: Mind, Body, and Not Death

Convention Center: Room 11

This session will provide a brief overview of palliative care and its use for the mental/emotion/physical toll of liver disease. It will dive into the practical applications for patients and providers. It will also educate patients on advocating for themselves if formal palliative care services are not available.



DOWNLOAD TLM'S MOBILE APP

For the most up-to-date information,
download the TLM mobile app.

11:00 AM-12:30 PM



Workshop

Transformative Impact of Artificial Intelligence on Basic Liver Research: From Predicting Protein Structure to Multimodal Data Integration, Part 2

Convention Center: Room 29

This workshop addresses how AI is revolutionizing the life sciences in hepatology and increasingly permeating the world of basic science. AI tools can be used for experimental design and modeling. AlphaFold, a landmark AI tool developed to predict protein conformation, is informing the development of small molecule inhibitors for different conditions. Other AI applications in basic research include sequencing, imaging, and structural biology. AI is being used to integrate clinical and high-throughput omics data for personalized diagnostic predictions and promises to inform individualized therapeutic approaches.

12:30-1:00 PM

TLM Theater

Addressing the Itch: HCP and Patient Perspectives on Managing Cholestatic Pruritus in PBC

*Supported by GSK US Medical Affairs***Convention Center: Exhibit Hall B, TLM Theater 1**

Join leading experts in hepatology and a patient advocate for an engaging discussion to gain perspective on optimizing the management of cholestatic pruritus in primary biliary cholangitis (PBC). Learn about the patient burden of cholestatic pruritus, addressing gaps in assessment, and opportunities to take a more patient-centric approach to management.

TLM Theater

Long-Term Data for GIVLAARI® (givosiran), including Clinical Case Reviews

*Supported by Alnylam Pharmaceuticals***Convention Center: Exhibit Hall B, TLM Theater 2**

Please join Alnylam Pharmaceuticals and Dr. Bruce Wang as he reviews long-term efficacy and safety data for RNA interference (RNAi) therapeutic GIVLAARI® (givosiran), featuring published data from the complete 36-month ENVISION Phase III trial. Dr. Wang will also share patient cases from his practice to provide clinical perspective on treatment with GIVLAARI.

12:30-2:00 PM



Satellite Symposium

Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient

*Supported by Madrigal Pharmaceuticals
Organized by Prova Education***Convention Center: Ballroom 20A**

This symposium will provide practical, interactive discussions of cardiometabolic pathophysiologic pathways, early identification and risk stratification, advances in treatment, monitoring for disease progression, and long-term medical management, including the role of incretin agonists.

Maximum of 1.50 AMA PRA Category 1 Credits™

For more information and to register, visit:

ReachMD.com/segment/26614

Satellite Symposium

Alpha-1 Antitrypsin Deficiency: Are You Overlooking a Leading Genetic Culprit in Liver Disease?

*Supported by Takeda Development Center Americas, Inc.
Organized by Clinical Care Options, LLC***Convention Center, Ballroom 20BC**

Alpha-1 antitrypsin deficiency associated (AATD) is a leading genetic cause of liver disease, yet it remains largely underdiagnosed and poorly understood. This interactive symposium features a multispecialty expert panel to provide insights into the pathophysiologic and genetic underpinnings, best practices in diagnosing, and navigating the management of AATD liver disease.

Maximum of 1 AMA PRA Category 1 Credit™

For more information and to register, visit:

clinicaloptions.com/events/alpha-1-antitrypsin-deficiency-liver-disease/12491

12:30–2:00 PM

 Social & Other Events

Past Presidents' Luncheon 

Convention Center: Room 1

12:45–1:30 PM

 Meet the Expert

MTE #22: Adjuvant Therapy for Hepatocellular Carcinoma: Standard of Care? 

Convention Center: Room 33A

Faculty discuss findings from IMbrave-050 and EMERALD-1 clinical trials and ongoing studies (CheckMate 9DX, KEYNOTE-937, EMERALD-2, et al.) that inform the utilization of immunotherapy in the adjuvant setting after surgery or locoregional therapy (LRT).

 Meet the Expert

MTE #23: Endothelial Cells in Chronic Liver Disease and Portal Hypertension 

Convention Center: Room 33B

Join this bench-to-bedside interactive discussion about the role and importance of liver endothelial cells in the pathogenesis of intrahepatic portal hypertension. Topics include basic concepts regarding sinusoidal endothelial cell biology and important molecular factors that influence the function of these cells.

 Meet the Expert

MTE #24: Optimizing Reproductive Health: Special Considerations for Cholestatic and Autoimmune Liver Disease and Liver Transplant 

Convention Center: Room 33C

Experts address the timing of pregnancy in relation to liver transplant (LT), graft function, and recurrence of chronic active liver disease post liver transplant (post-LT). Faculty also discuss immunosuppression safety in pregnancy and breastfeeding, and the distinct maternal and perinatal risks of post-LT pregnancy.

 Meet the Expert

MTE #25: Balancing Act of Immunosuppression: Not Too Much, Not Too Little 

Convention Center: Room 28E

Experts update attendees about antibody-mediated rejection, acute cellular rejection, and the role of precision medicine in immunosuppression adjustment. Topics include the principles of immunosuppression in liver transplantation, the diagnosis and management of antibody-mediated rejection, and the role of biomarkers in immunosuppression adjustment.

 Meet the Expert

MTE #26: Expanding the Hepatology Workforce: Incorporating Hepatology Associates Into Clinical Practices 

Convention Center: Room 30E

Presenters discuss ways to incorporate hepatology associates (e.g., registered nurses, nurse practitioners, physician assistants, pharmacists, and registered dietitians) into a clinical practice to increase access to hepatology care.

 Meet the Expert

MTE #27: Management of Acute Liver Failure Among Patients Listed for Transplant: Brain Matters | Meet the Expert 

Convention Center: Room 31A

Expert presenters focus on how to manage neurological complications in patients with acute liver failure (ALF) listed for transplant. Faculty review the diagnosis of cerebral edema, the role of new noninvasive diagnostic techniques, and management and prognosis.

 Meet the Expert

MTE #28: New Hepatitis B Treatments: What Is in Evolution? 

Convention Center: Room 31B

Speakers provide updates on new curative-intent HBV medications in development and what is new in the HBV treatment development landscape.

1:30-2:00 PM

TLM Theater

MASH Matters: The Evolving Management of Patients with Metabolic Dysfunction Associated Steatohepatitis*Supported by Boehringer Ingelheim International GmbH***Convention Center: Exhibit Hall B, TLM Theater 1**

MASH prevalence is rapidly increasing in parallel with increases in obesity and other cardio-renal-metabolic diseases. An interactive case will explore clinical challenges and unmet patient needs.

TLM Theater

Patient Spotlight: Hear From an Adult with Alagille Syndrome and Explore Clinical Insights With a Pediatric Hepatologist*Supported by Mirum Pharmaceuticals***Convention Center: Exhibit Hall B, TLM Theater 2**

Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) are cholestatic liver diseases characterized by debilitating pruritus. In this session, Emma will share her perspectives as an adult with ALGS. In addition, Dr. Ajay Jain will examine the impact of cholestatic pruritus and the evolving treatment landscape.

2:00-3:30 PM

 Lecture**Clinical Management of Immune-Mediated Liver Diseases****Convention Center: Ballroom 6F**

Presenters review the management of autoimmune-mediated liver diseases including autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, and immune-mediated DILI. The program also includes a panel discussion of a complex clinical case followed by a question-and-answer period.

2:00-3:30 PM

 Lecture**General Hepatology Update****Convention Center: Ballroom 6A**

The General Hepatology Update is dedicated to three topics of interest to broad clinical hepatology practice. The session focuses on updates and practical approaches to common clinical scenarios encountered in daily practice by experts in the disease state.

 Patient Programming**Healthcare Begins with Self-Care****Convention Center: Room 11**

An interactive session highlighting the need for and benefits of self-care within liver disease.

 Lecture**Inclusion and Diversity Committee Symposium: Tools to Improve Liver Health Equity****Convention Center: Ballroom 6D**

Health disparities in liver disease have long been recognized to affect liver disease morbidity and mortality. There are growing efforts to leverage community-based organizations, electronic medical records (EMRs) and electronic health records (EHRs), social needs screening, and other tools to improve access and outcomes for vulnerable populations. These tools, however, are often developed and implemented in silos around the country. This session provides a platform for sharing strategies, successes, and failures in efforts to improve health disparities in liver disease.

 Lecture**Stump the Hepatologist****Convention Center: Room 30ABCD**

The Stump the Expert session is designed to demonstrate the art behind the science of working through differential diagnosis for unknown cases. Through live interactions with the case presenters, hepatology experts will work through interesting and challenging cases and speak out loud their thought process as the case unfolds. During the process, participants will be able to witness how experts in the field, using their knowledge base, break down and narrow their differential diagnosis to solve a case. This session will focus on differential diagnosis and management of topics relevant to both pediatric and adult hepatology.

2:00–3:30 PM

Lecture

The Editors Cut: Basic and Translational Studies

Convention Center: Room 29

Associate Editors from the journal HEPATOLOGY, Drs. Kari Nejak-Bowen, Natalie Torok, and Samar Ibrahim, discuss the most notable, influential, cutting-edge, game-changing basic and translational research papers published in HEPATOLOGY and elsewhere during the past year. A panel discussion with HEPATOLOGY Editor-in-Chief Dr. Gregory Gores and HEPATOLOGY Deputy Editor Dr. Harmeet Malhi focuses on the impact of selected papers on basic and translational advances in the field.

Parallel Session

Risk Stratification of Donors and Candidates for Liver Transplantation

Convention Center: Ballroom 6B

Parallel Session

Advances in Pediatric Liver Disease: Basic and Translational

Convention Center: Ballroom 6C

Parallel Session

MASLD and MASH-New Therapies

Convention Center: Hall A: General Session

Parallel Session

Translational Strategies for Inflammatory-Driven Liver Disease: Immune Modulation and Tissue Remodeling

Convention Center: Room 28ABCD

3:30–4:15 PM

TLM Theater

A Deep Dive into MASH: Exploring the Role of Metabolic Dysfunction in Disease Pathophysiology

Supported by Novo Nordisk, Inc.

Convention Center: Exhibit Hall B, TLM Theater 1

This presentation will examine MASH (metabolic dysfunction-associated steatohepatitis) and the role of cardiometabolic dysfunction in disease development and progression. We will also discuss current AASLD guidelines regarding screening and management of patients at high-risk for advanced disease.

TLM Theater

Optimizing the Treatment Pathway for Patients with PBC

Supported by Intercept Pharmaceuticals, Inc.

Convention Center: Exhibit Hall B, TLM Theater 2

Join us for an informative presentation that discusses liver health and taking treatment for primary biliary cholangitis (PBC) a step further. Learn about an approved therapy for patients with PBC.

3:30–4:30 PM

Social & Other Events

SIG Meet Ups-Day 2

Convention Center: Sails Pavilion, The Park @ TLM Meet up #1-5

Join one of our Special Interest Group meet ups to connect with professionals who share your specific research and clinical interests. These networking opportunities offer a platform for in-depth discussions and potential collaborations. The SIGs meeting at this time are listed below:

- Portal Hypertension: Clinical and Experimental-Meet up #1
- Alcohol-Associated Liver Disease (ALD)-Meet up #2
- Liver Transplantation and Surgery (LTS)-Meet up #3
- Liver Cell Biology-Meet up #4
- Clinical Practice-Meet up #5

3:45–4:45 PM

 Community Conversations

Financial Models for Liver Transplantation: Challenges and Opportunities

Convention Center: Room 23

Speakers in this session discuss the various financial models, team dynamics, and incorporation of financial liability associated with newer techniques to optimize organ transplant efficiency.

 Community Conversations

Controversies in Management of Patients with Cirrhosis and Portal Hypertension

Convention Center: Room 1

Discuss changes in portal hypertension management, including controversies, and provide an open forum for questions.

 Community Conversations

NIH Corner – NIDDK

Convention Center: Ballroom 6E

Update for AASLD members on the challenges and opportunities in basic and clinical research funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

 Workshop

Transplant Program Directors Workshop

Convention Center: Room 1

In this session, presenters will provide updates on the current state of the Transplant Hepatology fellowship program, including the candidate match and revisions to the specialty blueprint, as well as issues related to the future health of the Transplant Hepatology fellowship.

 Special Interest Group (SIGs) Business Meetings

• **Hepatology Associates**

Convention Center: Ballroom 6F

The AASLD SIG Business Meetings at TLM offer members of the Special Interest Groups a chance to connect with the steering committee and discuss pertinent initiatives and programming.

5:00–6:30 PM

 Lecture

Exogenous Hormone Use Across Diverse Patient Populations With Liver Disease

Convention Center: Ballroom 6D

Jointly hosted by the AASLD Women’s Initiative Committee and the LGBTQ Task Force, this program includes three talks followed by a case presentation (with a question-and-answer period) to address the indications, safety, and efficacy of hormonal therapy across diverse populations with liver disease and liver transplant. Presentation topics include: (1) the safety of gender-affirming hormonal therapy in the context of liver conditions and the risk of liver-related morbidity related to hormonal therapy (i.e., DILI) within the growing population of transgender adolescents and adults; (2) the safety and efficacy of estrogen-and progestin-containing contraceptive agents—presented in the context of the US Centers for Disease Control and Prevention 2024 updated contraception guidelines in liver conditions—across the spectrum of liver disease, including post liver transplant; and (3) the safety, efficacy, and potential benefits of testosterone and estrogen therapy in older men and women with liver disease and liver transplant.

 Lecture

Optimizing Care for the Hospitalized Patient With Cirrhosis

Convention Center: Room 28ABCD

Experts in the field of inpatient hepatology care and quality improvement outline the challenges and practical patient-oriented and health system-oriented solutions to improve access to care; optimize inpatient clinical care; and provide patient-centered, compassionate care for persons hospitalized with decompensated cirrhosis. Covered topics include the management of ascites, acute-on-chronic liver failure, alcohol-associated hepatitis, and other complications of decompensated cirrhosis. Each presentation includes a discussion of health care disparities and strategies to mitigate these disparities.

5:00–6:30 PM

Patient Programming

Putting on the Spectacles to See the Spectrum of MetALD

Convention Center: Room 11

In this session, we are demystifying the new term MetALD by providing the definition, new diagnostics, and relevance to treatments for patients.

Workshop

Practice Guideline Session

General Session: Hall A

Step into the future of hepatology with this dynamic session on the latest in AASLD's Practice Guidelines. Led by esteemed experts in the field, this session promises to delve deep into cutting-edge research, innovative treatments, and practical applications that are shaping the landscape of liver care today.

Parallel Session

MASLD and MASH-Diagnostic Criteria

Convention Center: Ballroom 6A

Parallel Session

Novel Interventions in the Diagnosis and Treatment of Liver Diseases

Convention Center: Ballroom 6B

Parallel Session

Genomics: A Path to Precision Medicine

Convention Center: Ballroom 6C

Parallel Session

The Role of Advanced Practice Providers in HCV and MASLD

Convention Center: Room 6F

Parallel Session

Basic Mechanisms in the Pathogenesis and Prognosis of Alcohol-Associated Liver Disease

Convention Center: Room 29

5:45–6:45 PM

Social & Other Events

Hepatology Associates Reception

Convention Center: Members Lounge, Room 4

Connect with your peers at the Hepatology Associates Reception, an exclusive event tailored for APPs. This reception offers a unique opportunity to network, share insights, and build meaningful connections that will support your professional development and enhance your experience in the field of hepatology.

7:00–8:00 PM

Social & Other Events

Fellows' Reception 🎉

Marriott Marquis: Marriott Marquis Grand Ballroom Terrace

Celebrate your achievements and connect with peers at the Fellows' Reception, a special event dedicated to our FAASLDs and AF-AASLDs. This reception offers a special opportunity to network with fellow leaders and build lasting professional relationships within the hepatology community.

7:30–11:00 PM

Social & Other Events

Members' Reception 🌟

Marriott Marquis: Marriott Marquis Grand Ballroom

Join us at the Members' Reception, an exclusive members-only event designed to celebrate and appreciate our dedicated AASLD members. This evening gathering provides an excellent opportunity to reconnect with fellow members, share your experiences, and engage with AASLD leadership.

7:00–7:45 AM

 Meet the Expert

MTE #29: New Challenges: Pediatric Drug-Induced Liver Injury on the Rise 

Convention Center: Room 33A

Presenters discuss DILI diagnostic strategies and the most implicated agents in hepatotoxicity in the pediatric population.

 Meet the Expert

MTE #30: Drug-Induced Autoimmune-Like Hepatitis: Diagnostic and Therapeutic Challenges 

Convention Center: Room 33B

Experts discuss the drugs that commonly mimic autoimmune hepatitis and the challenges associated with diagnosis and management of this disorder.

 Meet the Expert

MTE #31: Use of Hepatitis C Virus Positive Donor Organs in Hepatitis C Virus Uninfected Solid Organ Transplant Recipients 

Convention Center: Room 33C

Using high-risk donors, including those who are infected with HCV, is a strategy to increase organ supply. The use of direct-acting antiviral therapy has paved the way for the use of HCV-viremic organs, changing the landscape of solid organ transplantation (SOT). Experts in this session review and discuss the data on the use of HCV-infected donor organs in SOT.

 Meet the Expert

MTE #32: Clinical Utility of Genomic Analysis in the Diagnosis and Management of Liver Disease 

Convention Center: Room 28E

The presenters review emerging data regarding genomic analysis in the evaluation of adults with liver disease. The speakers discuss what categories of liver disease are enriched in genetic liver diseases and the importance of multidisciplinary forums to integrate genetic data with clinical impression. This session focuses on Wilson disease, hemochromatosis, and alpha-1 antitrypsin deficiency as well as the utility of genomics-informed hepatology.

 Meet the Expert

MTE #33: Matrix Stiffness, Liver Injury, and Cancer 

Convention Center: Room 30E

Experts discuss the relationships between matrix stiffness, liver injury, and carcinogenesis. Presenters highlight the effects of steatosis on hepatic stellate cell activation and subsequent promotion of fibrogenesis; how liver stiffness due to chronic injury perpetuates liver disease processes; and how steatosis and steatohepatitis promote carcinogenesis through regulation of matrix stiffness.

 Meet the Expert

MTE 34: Current and Emerging Pharmacotherapy for Alcohol-Associated Liver Disease and Alcohol-Associated Hepatitis 

Convention Center: Room 31A

Presenters provide an in-depth analysis of the latest pharmacologic treatments for alcohol-associated liver disease (ALD) and alcohol-associated hepatitis (AH). Speakers focus on understanding the mechanisms, efficacy, and safety profiles of current medications as well as promising therapies in development. The session aims to equip health care professionals with knowledge to enhance patient outcomes through cutting-edge pharmacotherapy interventions.

 Meet the Expert

MTE #35: Glucagon-Like Peptide-1 Receptor Agonists and Other Drugs for Metabolic Dysfunction-Associated Steatotic Liver Disease: What Is the Update? 

Convention Center: Room 31B

In this session, experts update attendees on the latest research and clinical advancements concerning the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and other pharmaceuticals for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD). Presenters provide valuable insights into the mechanisms underlying these treatments and discuss how to apply this knowledge effectively in clinical practice. Additionally, experts instruct attendees on how to develop the ability to critically evaluate emerging trends and evidence, thereby promoting evidence-based decision-making for MASLD management.

8:00–9:30 AM

 State of the Art (SOA)

Leon Schiff SOA: Hepatic Encephalopathy, and Clinical Plenary 2

Convention Center: Hall A: General Session

Hepatic encephalopathy is a devastating and underappreciated complication of cirrhosis that impacts patients, their families, the health care system, and society. Gut-liver-brain axis alterations are key drivers of hepatic encephalopathy-related pathophysiology. These alterations are increasingly being leveraged to enhance diagnostic specificity and treatment targets. The hepatic encephalopathy spectrum includes covert to overt stages; each presents unique challenges in diagnosis, management, and recurrence prevention. Recognizing the challenges and opportunities with currently available hepatic encephalopathy therapies and those on the horizon is critical for improving patient outcomes.

 Course

Point of Care Liver Ultrasound: The Next Frontier, Part 1 [Session A] *SOLD OUT*

Convention Center: Room 30ABCD

This symposium will introduce the concept of point of care ultrasound (POCUS) of the liver as an extension of the clinical exam to be performed by hepatology providers. The symposium will provide a rationale for the use of POCUS, basics of liver ultrasonography, common applications, and a path to implement POCUS in clinical practice.

 Course

AASLD/SITC Joint Course: The Present and Future State of Immune Therapy and Care Delivery For Liver Cancer

Convention Center: Ballroom 6E

Multidisciplinary care is essential for the optimal management of patients with liver cancer. Hepatologists play a central role in liver cancer care by assessing and managing underlying liver disease. Skills unique to hepatology include stratifying severity of liver disease, identifying and managing portal hypertension, understanding liver metabolism, and managing liver-related toxicity of immune and other oncologic therapies.

The overall goal of this program is to introduce and discuss novel paradigms of HCC management and the integration of hepatology into the systemic therapy of HCC. In the first session, we will explore European and Asian models of care delivery, assess the current state of systemic therapies, consider real-world application of clinical trials data to complex cases, and understand how to anticipate and manage side effects of systemic therapy.

 Lecture

American Association for the Study of Liver Diseases (AASLD) and Japan Society of Hepatology (JSH) Joint Symposium: Navigating Bleeding Complications in Cirrhosis, Strategies for Effective Management

Convention Center: Ballroom 6D

The American Association for the Study of Liver Diseases and the Japan Society of Hepatology joint symposium is a practical program geared toward both hepatologists and nonhepatologists that focuses on effective management of portal hypertension-related bleeding. The program reviews approaches to optimize patient outcomes by integrating diverse strategies for managing portal hypertension complications through collaborative learning exchanges. Presentation topics include strategies for the prevention of procedure-related bleeding, the latest approaches to managing cirrhosis-related coagulopathy and thrombocytopenia, and expert guidance on the treatment of esophageal and gastric variceal bleeding.

8:00–9:30 AM

 Parallel Session

Hepatitis C-Epidemiology, Biomarkers, Fibrosis and HCC

Convention Center: Ballroom 6A

 Parallel Session

Hepatitis B–Novel Therapeutic Targets and Preclinical Studies

Convention Center: Ballroom 6B

 Parallel Session

From Bench to Bedside: State of the Art Diagnostics and Therapeutics in Genetic and Metabolic Liver Disease

Convention Center: Ballroom 6C

 Parallel Session

Biliary Physiology, Transport, Cholangiocyte Biology, Experimental Cholestasis

Convention Center: Room 6F

 Parallel Session

MASLD Translational Targets

Convention Center: Room 28ABCD

 Parallel Session

Hepatotoxicity–New Insights Regarding Mechanisms and Prognostication

Convention Center: Room 29

8:00 AM–5:00 PM

 Posters Session

Monday Poster Presentations

Convention Center: Hall C, Poster Hall

Monday posters hall will feature:

- Acute Liver Failure and Artificial Liver Support
- Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis
- Cell and Molecular Biology
- Genomics and Precision Medicine
- Human Cholestatic and Autoimmune Liver Diseases
- Metabolic and Genetic Disease
- MASLD/MASH: Treatment–Non-Pharmacologic
- Pediatric Hepatology
- Portal Hypertension and Other Complications of Cirrhosis

Each poster session is categorized by topic and marked with a corresponding color for easy identification in the hall.

Poster presentations take place from 1:00–2:00 PM.

9:45–10:45 AM

 Social & Other Events

Hepatology Associates SIGs in The Park

Convention Center: Sails Pavilion, The Park @ TLM

Join our Hepatology Associates Special Interest Group meetup to connect with professionals who share your specific research and clinical interests.

 Community Conversations

ECI Essentials: Future-Proofing Your Research Portfolio

Convention Center: Ballroom 6D

In today's fiercely competitive funding environment, an investigator's long-term success depends on their ability to secure grant support during their scientific training and early years in academic medicine. This program will provide attendees with strategies to ensure a sustainable future career as an independent investigator, including how to develop a diverse, future-proof research portfolio, how to find and apply for the right extramural funding opportunities, and how to craft a resubmission application if your initial proposal is not funded.

9:45-10:45 AM

 Community Conversations**Maintenance of Certification: Updates on Staying Current With the American Board of Internal Medicine****Convention Center: Room 1**

In this session, presenters discuss updates regarding the American Board of Internal Medicine maintenance of certification requirements, and strategies to remain up to date with the process of certification.

 Community Conversations**Management of Obesity and Liver Disease: What's New and Trending in Obesity Medicine****Convention Center: Room 24**

Speakers in this Community Conversations program review hot topics in obesity medicine and how they relate to hepatology. Topics addressed include nutrition, bariatric surgery, and endoscopy, and how each relates to obesity medicine and liver disease. A successful program that employs a multidisciplinary approach in applying obesity medicine treatment with consideration of the patient with chronic liver disease is reviewed. Presenters also discuss the new glucagon-like peptide-1 (GLP-1) receptor agonist medications, their efficacy, and the science behind the buzz.

 Community Conversations**NIH Corner CDC-DVH****Convention Center: Ballroom 6E**

CDC's Division of Viral Hepatitis Director Carolyn Wester will discuss the ongoing work at DVH and the division's role in the White House Hepatitis C Elimination plan.

 Community Conversations**Reproductive Health and Impact on Patients with End-Stage Liver Disease****Convention Center: Room 23**

Panelists in this Community Conversation discuss complex cases involving reproductive health and pregnancy in persons with ESLD and liver transplantation. The panel includes a patient representative, a maternal fetal medicine specialist, an obstetrician, and a hepatologist. The session consists of individual presentations addressing current evidence-based guidance/guidelines around the topic followed by an interactive panel discussion of challenging clinical scenarios. The panel reviews current American Association for the Study of Liver Diseases (AASLD) guidance and the European Association for the Study of the Liver (EASL) guidelines addressing the approach to management of pregnancy in the setting of ESLD post liver transplant.

10:00-10:45 AM

TLM Theater**Rezdiffra (resmetirom) – A Treatment Option for Patients**

Supported by Madrigal Pharmaceuticals, Inc.

Convention Center: Exhibit Hall B, TLM Theater 1

Please join us for an engaging and highly anticipated educational presentation focusing on Rezdiffra and its clinical data.

10:00–10:45 AM

TLM Theater

TERLIVAZ® (terlipressin): The First FDA-Approved Treatment for HRS in Adults with Rapid Reduction in Kidney Function

Supported by Mallinckrodt Pharmaceuticals

Convention Center: Exhibit Hall B, TLM Theater 2

Consider treatment with the first and only FDA-approved drug for HRS in adults with rapid reduction in kidney function: TERLIVAZ® (terlipressin). Terlipressin is recommended by AASLD Guidance and ACG guidelines. Demonstrated a significantly higher rate of verified HRS reversal, defined as improvement in renal function, avoidance of dialysis, and short-term survival. Treatment earlier in disease progression was associated with a higher rate of HRS reversal and lower rate of respiratory failure. Terlipressin can be used to treat patients outside of the ICU on the regular medical floor. The most commonly observed adverse reactions in patients treated with terlipressin were abdominal pain, nausea, respiratory failure, diarrhea, and dyspnea.

10:00 AM–12:00 PM

 Course

Point-of-Care Liver Ultrasound: The Next Frontier, Part 2 [Session A]  *SOLD OUT*

Room 30ABCD

This course introduces the concept of point-of-care ultrasound (POCUS) of the liver as an extension of the clinical exam performed by hepatology professionals. The symposium reviews the rationale for use of POCUS; the basics of liver ultrasonography; common applications of liver ultrasonography; hands-on-training in a simulated environment; and a proposed path to implement liver POCUS in clinical practice.

11:00 AM–12:30 PM

 State of the Art (SOA)

Hans Popper SOA: Adaptive Immunity in Autoimmune Diseases, and Basic Science Plenary

Convention Center: Hall A: General Session

This session explores the role of adaptive immunity in the development and progression of autoimmune diseases.

 Course

Developing the Hepato-Oncology Workforce

Convention Center: Ballroom 6E

Multidisciplinary care is essential for the optimal management of patients with liver cancer. Hepatologists play a central role in liver cancer care by assessing and managing underlying liver disease. Skills unique to hepatology include stratifying severity of liver disease, identifying and managing portal hypertension, understanding liver metabolism, and managing liver related toxicity of immune and other oncologic therapies.

Workforce demands in hepatology and oncology provide opportunities for cross discipline innovations in discovery and care delivery. In session 2 we will explore the regulatory, logistical, and infrastructural needs of systemic therapy delivery and models of combined specialty training. As the landscape of therapies evolves for liver cancer, we will consider the future of systemic therapy and how the AASLD can promote innovation in the field.

 Lecture

Are We Ready to Ride the Wave of Artificial Intelligence?

Convention Center: Room 29

This session—held two years after the release of ChatGPT—covers updates and advancements in the applications of generative AI (GenAI) in liver diseases. The discussion builds on previous introductory sessions at The Liver Meeting 2023 and Digestive Disease Week 2024. Presenters explore advanced topics including: (1) AI alignment, i.e., ensuring that an AI system’s objectives align with human values and goals, such as whether AI gives factually correct and safe answers in response to questions about liver diseases; (2) commercially available AI tools deployed within EHRs and adjacent to EHRs (e.g., AI scribe technologies) that have a hepatology focus; and (3) human-computer interactions in GenAI relevant to applications in clinical hepatology.

11:00 AM-12:30 PM

 Lecture**Behind the Scenes of Steatotic Liver Disease: From Research Idea to High-Impact Publication**

Convention Center: Room 28ABCD

In this clinical research fireside chat, authors of manuscripts published in high-impact journals that address the spectrum of steatotic liver disease with diverse research methodologies discuss their work—from study conception to implications of study findings. The session provides an in-depth exploration of the research process from the perspective of the investigator and their team. Presenters briefly discuss how they took an initial idea to study design to execution and publication. Presentations are followed by a more informal and interactive discussion between the presenters and moderators within the framework of a critical review, with a focus on challenges encountered during the process and creative strategies to overcome them. This program provides an opportunity for clinical attendees to explore the findings of recent, high-impact steatotic liver disease publications.

 Parallel Session**Portal Hypertension and Other Complications of Cirrhosis**

Convention Center: Ballroom 6A

 Parallel Session**Alcohol-associated Hepatitis: Updates in Diagnosis, Prognosis, and Therapy**

Convention Center: Ballroom 6B

 Parallel Session**Hepatitis B: Natural History and Biomarkers**

Convention Center: Ballroom 6C

 Parallel Session**Burdens to Bear: Trends in the Challenges and Costs of Liver Disease-Related Care**

Convention Center: Room 6D

 Parallel Session**Human Cholestatic, PBC and Other Biliary Disorders in Children and Adults**

Convention Center: Room 6F

 Parallel Session**Hepatitis D: Natural History and Treatment**

Convention Center: Ballroom 6C

 Parallel Session**Exploring Disparities and Determinants in Liver Disease and Care**

Convention Center: Ballroom 6D

 Parallel Session**Hepatobiliary Neoplasia—Tumor Microenvironment and Carcinogenesis**

Convention Center: Ballroom 6E

 Parallel Session**Cell-Based Approaches to Understanding and Treating Liver Disease**

Convention Center: Room 6F

 Parallel Session**Updates in Acute on Chronic Liver Failure**

Convention Center: Room 28ABCD

 Parallel Session**Advances in Treatment of Hepatitis C**

Convention Center: Room 29

12:30–1:00 PM

TLM Theater

Unlocking the Genetic Architecture of Steatotic Liver Disease (NASH)

Supported by GSK

Convention Center: Exhibit Hall B, TLM Theater 1

This panel will explore the genetic architecture of steatotic liver disease (SLD) and its impact on managing advanced liver disease. Experts will discuss unmet needs, key genetic drivers, like HSD17B13, how factors like alcohol and diet influence disease progression, and how genetics can shape the future therapeutic strategies for SLD.

TLM Theater

Unlocking Treatment Possibilities in PBC

Supported by Ipsen Biopharmaceuticals, Inc.

Convention Center: Exhibit Hall B, TLM Theater 2

Discover the latest in PBC advancements with Dr. Sammy Saab.

12:30–2:00 PM

 Satellite Symposium

Itching for More: Improving Care of Pruritus in PBC

Supported by GlaxoSmithKline

Organized by Clinical Care Options, LLC

Convention Center: Ballroom 20 BC

Cholestatic pruritus can have devastating impacts on a patient's quality of life. This interactive symposium will feature expert hepatologists and a patient, offering insights into the burden of cholestatic pruritus in PBC, its impact on quality of life, current best practices for assessment and management, and emerging therapies.

Maximum of 1.5 AMA PRA Category 1 Credit(s)[™]

For more information and to register, visit:

clinicaloptions.com/2024PBCpruritusSanDiego

 Social & Other Events

Women's Networking Luncheon *SOLD OUT*

Supported by Madrigal Pharmaceuticals

Convention Center: Room 1

A dedicated luncheon to celebrate and empower women in hepatology. Network with female leaders in the field, discuss challenges and opportunities, and build a supportive community.

12:45–1:30 PM

 Meet the Expert

MTE #36: Managing Challenging Benign and Malignant Liver Lesions Before, During, and After Pregnancy

Convention Center: Room 33A

The management of liver lesions in pregnancy is becoming more common given the increase in persons with chronic liver disease and cirrhosis achieving pregnancy. In this session, experts review an approach to and management considerations for liver lesions in pregnancy and the peripregnancy period, including both benign (hepatic adenoma) and malignant (HCC) masses.

 Meet the Expert

MTE #37: Management of Portal Vein Thrombosis

Convention Center: Room 33B


Experts in this clinically focused session present information centered around the diagnosis and management of portal vein thrombosis (PVT). Topics include the pathogenesis of PVT and best practices for the management of acute and chronic PVT, including both pharmacologic and interventional approaches. Presenters intend the session to be an interactive discussion between the moderators and attendees.

12:45-1:30 PM

 Meet the Expert**MTE #38: The Crosstalk of Immune Cells and Portal Fibroblasts in Liver Fibrogenesis** 

Convention Center: Room 33C

Portal fibroblasts (PFs) are implicated in the pathogenesis of cholestatic fibrosis. Proliferation and activation of PFs is mediated by the crosstalk between immune cells and cholangiocytes. Experts discuss pathways of PF activation; composition and heterogeneity of PFs; functional roles of PFs and hepatic stellate cells; and potential strategies for the development of novel antifibrotic therapies for the treatment of cholestatic fibrosis.

 Meet the Expert**MTE #39: Mitochondrial Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: Targeting Fibrosis and Hepatic Damage** 

Convention Center: Room 28E

Speakers discuss the role of intracellular intricacies, including mitochondrial proteins, and their role in fatty liver disease as it relates to hepatic fibrosis. Presenters also describe human disease progression in obese and lean patient disease phenotypes along with animal models recapitulating metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).

 Meet the Expert**MTE #40: Coagulopathy in Acute-on-Chronic Liver Failure** 

Convention Center: Room 30E

In this session, acute-on-chronic liver failure (ACLF) SIG members present cases of patients with coagulopathy and ACLF. Experts present the evidence supporting the assessment and management of coagulopathy in patients with advanced chronic liver disease. The session concludes with a question-and-answer period with the experts and attendees.

 Meet the Expert**MTE #41: Lifestyle Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease Care: From Guidance to Personalized Prescription** 

Convention Center: Room 31B

Explore the spectrum of lifestyle recommendations for effective care in metabolic dysfunction-associated steatotic liver disease (MASLD), from general guidance to personalized prescriptions. This course provides health care professionals with comprehensive insights into tailoring lifestyle interventions to meet individual patient needs. Presenters dive into dietary, exercise, and behavioral strategies while communicating the latest research findings, enabling clinicians to optimize MASLD management through personalized care plans.

**DOWNLOAD TLM'S MOBILE APP**

For the most up-to-date information,
download the TLM mobile app.

1:30–2:00 PM

TLM Theater

Shaping the Future: Clinical Validation of a Multi-Analyte Blood Test for Early HCC Detection

Supported by Helio Genomics

Convention Center: Exhibit Hall B, TLM Theater 1

HelioLiver, an advanced blood test for early HCC detection, has shown superior performance over ultrasound, especially in identifying HCC lesions ≤ 4 cm. Join us to dive into these promising findings and their significant impact on the liver cancer landscape.

TLM Theater

Unraveling Genetic Causes of a Cholestatic Liver Disease and a Review of a Treatment Option

Supported by Ipsen Biopharmaceuticals, Inc.

Convention Center: Exhibit Hall B, TLM Theater 2

Join us for a presentation starting with Dr. Amber Hildreth discussing genetic causes of cholestatic liver disease followed by Dr. Edward Mena with an overview of a possible treatment option for your pediatric and adult patients.

2:00–3:30 PM

 Late Breaking Abstract

Oral Abstracts, Session 1

Convention Center: Hall A: General Session

 Lecture

Advanced Diagnostics and Monitoring for Hepatocellular Carcinoma

Convention Center: Ballroom 6E

This comprehensive session, developed in partnership with the American Society for Clinical Oncology (ASCO), aims to address the latest advancements in hepatocellular carcinoma (HCC) diagnosis and monitoring, with a special focus on molecular-based targeted therapies, ctDNA and pioneering imaging techniques like immuno-PET and MR spectroscopy. Participants will gain a deeper understanding of how ctDNA analysis can improve not only HCC diagnosis but also prognosis and treatment monitoring. We will also explore the role of radiomics, and novel imaging modalities such as immuno-PET and MR spectroscopy, in improving the accuracy of HCC diagnosis and treatment planning. The session aims to bridge critical knowledge gaps by showing the potential integration of these advanced technologies into personalized patient management.

 Course

Point-of-Care Liver Ultrasound: The Next Frontier, Part 1 [Session B]  ***SOLD OUT***

Convention Center: Room 30ABCD

This symposium will introduce the concept of point-of-care ultrasound (POCUS) of the liver as an extension of the clinical exam to be performed by hepatology providers. The symposium will provide a rationale for the use of POCUS, basics of liver ultrasonography, common applications and a path to implement POCUS in clinical practice.

2:00-3:30 PM



Workshop

Transforming the Future of Hepatology: Clinical Research Innovations That Improve Diagnostic Methods, Trial Design, and Patient Outcomes, Part 1

Convention Center: Room 28ABCD

This two-part workshop is dedicated to fostering innovation and collaboration in hepatology research. In Part 1, invited talks led by top experts introduce attendees to forward-thinking perspectives on essential research aspects, including cohort design, biomarker development, and clinical trials, providing a rich base for informed conversations. Part 2 deepens the discussions in breakout sessions where experts and junior faculty jointly tackle practical issues of cohort development, biomarker development, and clinical trials. This workshop promises a stimulating environment for attendees to engage in robust discussions and learn from each other with the goal of driving improvements in hepatology research and, ultimately, patient outcomes.

3:30-4:15 PM

TLM Theater

Point-of-Care Testing for HCV RNA: Innovating for Patient Impact Where and When It Matters

Supported by Cepheid

Convention Center: Exhibit Hall B, TLM Theater 1

The introduction of first POC HCV RNA test in the U.S. is set to revolutionize HCV elimination programs! Join our expert panel as they dive into how this game-changing solution is enabling innovative models of care that reach more people, speed up diagnosis, and improve linkage to care.

TLM Theater

Introducing a Novel, First-in-Class Treatment for Primary Biliary Cholangitis (PBC)

Supported by Gilead Sciences, Inc.

Convention Center: Exhibit Hall B, TLM Theater 2

Join us for an informative product theater session on a recent FDA-approved treatment option for primary biliary cholangitis (PBC). Discover how this novel therapy may improve PBC outcomes for appropriate patients affected by this chronic liver disease.

3:30-4:30 PM



Social & Other Events

SIG Meet Ups-Day 3

Convention Center: Sails Pavilion, The Park @ TLM Meet up #1-5

Join one of our Special Interest Group meet ups to connect with professionals who share your specific research and clinical interests. These networking opportunities offer a platform for in-depth discussions and potential collaborations. The SIGs meeting at this time are listed below:

- Liver Cancer-Meet up #1
- Hepatitis C-Meet up #2
- Acute on Chronic Liver Failure (ACLF)-Meet up #3
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Meet up #4
- Public Health/Health Care Delivery-Meet up #5

3:45-4:45 PM



Lecture

Metabolic Dysfunction-Associated and Alcohol-Associated Liver Disease (MetALD)

Room 24

Brought to you by the SLD taskforce, this session provides a deep dive on MetALD, to include the definition and epidemiology, diagnosing and treatment options for MetALD.



Community Conversations

AASLD TASL Community Conversation: Hepatitis Delta

Convention Center: Ballroom 6D

Join experts from the U.S. and Türkiye as they discuss the similarities and differences in addressing Hepatitis Delta between the two countries.

3:45–4:45 PM

 Community Conversations

AASLD-KASL 2024 Community Conversation

Convention Center: Room 1

The session will explore the integration of MASLD into AASLD guidelines, with emphasis on the methodologies and systematic review processes employed by AASLD to ensure the production of robust and comprehensive guidelines. This session will present AASLD's approach in the selection and exclusion of articles, evidence collection process for systematic reviews, and how the results from the SR are used appropriately in practice guidelines. This session will discuss the challenges faced in the establishment of clinical practice guidelines for NIT. It will address the issues and gaps found in the existing literature and propose strategies to overcome these challenges and advance future research.

 Community Conversations

Management of Hepatocellular Carcinoma in Africa

Convention Center: Room 23

Organized by the AASLD Global Outreach and Engagement Committee and the Society on Liver Diseases in Africa as a joint program, presenters in this session discuss the burden of HCC in Africa; current management guidelines for HCC in Africa; emerging basic science research on HCC in Africa; and current treatment approaches and ways of increasing access to systemic therapies for HCC in Africa.

 Community Conversations

NIH Corner–NIAAA

Convention Center: Ballroom 6E

National Institute of Alcohol Abuse and Alcoholism Director, Dr. George Koob, will present opening remarks on NIAAA's liver-related work and present on research opportunities and answer audience questions.

 Community Conversations

Metabolic Dysfunction–Associated and Alcohol–Associated Liver Disease (MetALD)

Convention Center: Ballroom 24

 Workshop

Transforming the Future of Hepatology: Clinical Research Innovations that Improve Diagnostic Methods, Trial Design, and Patient Outcomes, Part 2A Breakout Session (Cohort Development)

Convention Center: Room 28ABCD

This two-part workshop is dedicated to fostering innovation and collaboration in hepatology research. In Part 1, invited talks led by top experts introduced attendees to forward-thinking perspectives on essential research aspects, including cohort design, biomarker development, and clinical trials, providing a rich base for informed conversations. Part 2 deepens the discussions in breakout sessions where experts and junior faculty jointly tackle practical issues of cohort development, biomarker development, and clinical trials. This workshop promises a stimulating environment for attendees to engage in robust discussions and learn from each other with the goal of driving improvements in hepatology research and, ultimately, patient outcomes.

 Workshop

Transforming the Future of Hepatology: Clinical Research Innovations that Improve Diagnostic Methods, Trial Design, and Patient Outcomes, Part 2B Breakout Session (Biomarker Development)

Convention Center: Ballroom 6C

This two-part workshop is dedicated to fostering innovation and collaboration in hepatology research. In Part 1, invited talks led by top experts introduce attendees to forward-thinking perspectives on essential research aspects—including cohort design, biomarker development, and clinical trials—providing a rich base for informed conversations. Part 2 deepens the discussions in breakout sessions where experts and junior faculty jointly tackle practical issues of cohort development, biomarker development, and clinical trials. This workshop promises a stimulating environment for attendees to engage in robust discussions and learn from each other with the goal of driving improvements in hepatology research and, ultimately, patient outcomes.

3:45–4:45 PM



Workshop

Transforming the Future of Hepatology: Clinical Research Innovations that Improve Diagnostic Methods, Trial Design, and Patient Outcomes, Part 2C Breakout Session (Clinical Trials)

Convention Center: Ballroom 6F

This two-part workshop is dedicated to fostering innovation and collaboration in hepatology research. In Part 1, invited talks led by top experts introduce attendees to forward-thinking perspectives on essential research aspects—including cohort design, biomarker development and clinical trials—providing a rich base for informed conversations. Part 2 deepens the discussions in breakout sessions where experts and junior faculty jointly tackle practical issues of cohort development, biomarker development, and clinical trials. This workshop promises a stimulating environment for attendees to engage in robust discussions and learn from each other with the goal of driving improvements in hepatology research and, ultimately, patient outcomes.

4:00–6:00 PM



Course

Point-of-Care Liver Ultrasound: The Next Frontier, Part 2 [Session B] ***SOLD OUT***

Convention Center: Room 30ABCD

This course introduces the concept of point-of-care ultrasound (POCUS) of the liver as an extension of the clinical exam performed by hepatology professionals. The symposium reviews the rationale for use of POCUS; the basics of liver ultrasonography; common applications of liver ultrasonography; hands-on-training in a simulated environment; and a proposed path to implement liver POCUS in clinical practice.

5:00–6:30 PM



Late Breaking Abstract

Oral Abstracts, Session 2

Convention Center: Hall A: General Session



Debrief

TLM Debrief 1: Pediatric Liver Disease, Liver Transplantation, and Portal Hypertension

Convention Center: Ballroom 6A

The debrief sessions summarize the highest impact papers addressing key topics across the field of hepatology presented during The Liver Meeting. A group of original research reports reflecting major advances in hepatology are succinctly reviewed. Debrief 1 will cover pediatric liver disease, liver transplantation, and portal hypertension.

6:30–7:30 PM



Social & Other Events

Diversity Reception

Supported by Medscape Education

Marriott Marquis: San Diego Ballroom A

Join us at the Diversity Reception, hosted by the Inclusion and Diversity Committee and the Women's Initiative Committee. This special event is dedicated to celebrating and promoting diversity, inclusion, and belonging within the hepatology community. Engage in meaningful conversations, share experiences, and connect with colleagues who are passionate about fostering an inclusive environment.

7:00–9:00 PM



Social & Other Events

AASLD Foundation Emerging Liver Programs Closing Reception

8:00–10:30 AM

 Debrief

TLM Debrief 2: Basic Science, Hepatitis, HCC, Cholestatic, MASLD, Alcohol-Associated Liver Disease and MetALD Debrief

Convention Center: Hall A: General Session

The debrief sessions summarize the highest impact papers addressing key topics across the field of hepatology presented during The Liver Meeting. A group of original research reports reflecting major advances in hepatology are succinctly reviewed. Debrief 2 will address basic science research, hepatitis, hepatocellular carcinoma, cholestatic liver disease, alcohol-associated liver disease and MetALD, and metabolic dysfunction-associated liver disease.

10:30–11:30 AM

 Late Breaking Abstract

Oral Abstracts, Session 3

Convention Center: Hall A: General Session

YOUR TLM REGISTRATION GIVES YOU ACCESS TO



With 60-day complimentary access, go back and watch sessions you were unable to attend in San Diego—some sessions offer credits. Sessions include all General Sessions, including Postgraduate Course, State-of-the-Art lectures, patient programming, and the 2024 Honors & Awards Ceremony.

TAILORED PROGRAMMING TO EMPOWER YOUR HEPATOLOGY JOURNEY

No matter where you are in your career, The Liver Meeting offers ample opportunities for you to meet with like-minded hepatology champions.

FIRST-TIME ATTENDEES

Deepen your connections with peers and experts through a few highlighted programming and networking opportunities. View more sessions on the app!

Friday, November 15–Monday, November 18

SIGs in The Park

Join one of our Special Interest Group (SIG) meet ups to connect with professionals who share your research and clinical interests. These social opportunities offer a platform for in-depth discussions and potential collaborations.

Friday, November 15

8:00 AM–5:30 PM, Convention Center Hall A,
General Session:

Postgraduate Course, Parts 1–4: The Future Is Here—
Practicing Hepatology in 2024

Saturday, November 16

8:00–9:30 AM, Convention Center Ballroom 6B:
Metabolic Dysfunction–Associated Steatotic Liver
Disease, Alcohol–Associated Liver Disease, and
MetALD: Beyond the Nomenclature

6:00 AM–6:45 PM, Members Lounge, Room 4: First-Time Attendee Reception

This reception offers a warm and inviting atmosphere where first-time attendees can meet fellow newcomers and AASLD social media ambassadors to learn how to make the most of their first TLM.

Sunday, November 17

7:30–11:00 PM, Marriott Marquis:
Members' Reception for AASLD Members only

PATIENT & PATIENT ADVOCATES

Held by AASLD's Patient Advisory Group—a group of providers and patient advocates—The Liver Meeting offers 11 sessions and two unique networking opportunities at the Convention Center, Room 11.

Friday, November 15

7:00–8:00 AM: Patient Breakfast

8:00–9:30 AM: Patient Annual Forum



To view additional programming
opportunities, download
The Liver Meeting Mobile App.

HEPATOLOGY ASSOCIATES

Maximize your time with focused sessions tailored to deepen your knowledge and bring your voice to the table with valuable insights.

Friday, November 15–Monday, November 18

SIGs in The Park

Join one of our Special Interest Group (SIG) meet ups to connect with professionals who share your research and clinical interests. These social opportunities offer a platform for in-depth discussions and potential collaborations.

Friday, November 15

8:00 AM–5:30 PM, Convention Center Hall A, General Session:
Postgraduate Course, Parts 1–4: The Future Is Here—Practicing Hepatology in 2024

TRAINEES

Elevate your understanding of hepatology and fuel your passion for collaboration and networking with these opportunities.

Saturday, November 16

2:00–4:45 PM, Convention Center, Room 30: Academic Debate

Watch fellow trainees' debate on HCC Screening. This lively session showcases expertise, spirited discussions, and advancements in the field of liver disease. Come watch or play in the first AASLD TLM Pickleball Tournament!

7:00–7:45 PM, Member Lounge, Room 4:
Trainee Reception hosted by Liver Fellow Network

Sunday, November 17

7:30–11:00 PM, Marriott Marquis:
Members' Reception

Saturday, November 16

9:45–10:45 AM, Convention Center, Room 23:
Hepatology Associates as Leaders in HCV Eliminations Programs

Sunday, November 17

8:00 AM–12:30 PM, Convention Center, Room 6:
Hepatology Associates Course

2:00–3:30 PM, Convention Center, Room 6:
Hepatology Associates SIG: Clinical Management of Immune Meditated Liver Disease

5:45–6:45 PM, Member Lounge, Room 4:
Hepatology Associates Reception

GLOBAL

Experience The Liver Meeting's global impact through these global events and programming.

Sunday, November 17

8:00–9:30 AM, Convention Center, Ballroom 6D:
Global Symposium, Global Perspectives on Hepatocellular Carcinoma

9:45–10:45 AM, The Park @ TLM, Sails Pavilion:
Global Meet Up

Monday, November 18

3:45–4:45 PM, Convention Center, Room 3:
Community Conversation: Healthy Liver, Healthy Lives



DISCOVER THE PARK @ TLM, A BRAND-NEW EXPERIENCE FOR THE 75TH LIVER MEETING!

This lively space, located in the Sails Pavilion of the San Diego Convention Center, brings the outdoors inside and offers attendees a place to gather, connect, and rejuvenate. Come watch or play in the first AASLD TLM Pickleball Tournament!

THANK YOU, 2024 SPONSORS!

GOLD SPONSORS



SPONSORS



TLM Supporters as of October 8, 2024.

2024 LIVER MEETING EXHIBITORS

COMPANY NAME	BOOTH NUMBER
89bio	1610, MR23
AASLD Hub	711
AbbVie	739
AcariaHealth	1351
Akero Therapeutics	1051
Alagille Syndrome Alliance	746
ALEH	714
Alimentiv Inc.	1611
Alnylam	1141
Alpha-1 Foundation	1222
American Liver Foundation	728
American Porphyria Foundation	953
Amsety LLC	1417
Asian Pacific Association for the Study of the Liver (APASL)	716
AstraZeneca	1739, MR16, MR17, MR19
Autoimmune Hepatitis Association	744
Avant Santé	1153
BARE	1154
Bausch Health-Salix Medical Affairs	911
BD	1016
Bionutrigen Co., Ltd.	1622
BioPredictive	1420

COMPANY NAME	BOOTH NUMBER
Blue Faery	710
Boehringer Ingelheim Pharmaceuticals Inc.	1115, 1149, MR2
Boston Pharmaceuticals	1545, MR31
Carnegie Mellon University-Masters of Medical Management	1025
Cepheid	1133
CHESS	1056
Cholangiocarcinoma Foundation	732
Choose Health	1419
Chronic Liver Disease Foundation	1054
Clinical Care Options	1727
CIMA Sciences & Luxor Scientific	1451
Coalition For Global Hepatitis Elimination, Task Force For Global Health	712
Cochrane Hepato-Biliary	718
Community Liver Alliance	722, MR32
Cook Medical	1422
Corcept Therapeutics	1547
Cytotheryx, Inc.	1020
Diapharma Group	1139
Dynavax Technologies	919
Echosens	1523
Eieling Technology Limited	1825
Eisai Inc.	738, MR24
Eli Lilly and Company	1745
ENDRA Life Sciences	820

COMPANY NAME	BOOTH NUMBER
E-Scopics	1246
Eurofins Transplant Genomics	1513
European Association for the Study of the Liver (EASL)	721
Exact Sciences	1511
Exelixis	1433
Fibronostics-LIVERFASt	1724
Focus Medical Communications	1055
Fortrea	1624, MR9
Forum for Collaborative Research	749, 750
FUJIFILM Healthcare Americas Corporation	1325
Fujifilm VisualSonics Inc.	1323
Galaxy Zero	1011
Gastroenterology & Endoscopy	917
Gastro-Hep Communications Inc	1220
Genentech	1045
GenoBioTX	1833
Gilead Sciences, Inc.	727, 1517, MR11, MR12
Global Hepatitis Summit / Canadian Association for the Study of the Liver	1057
Global Liver Institute	846
GSK	1539, MR22, MR7
Gubra	1829
HealthWell Foundation	720
Helio Genomics	1730
Hepatiq Inc.	1147

COMPANY NAME	BOOTH NUMBER
HepQuant	1204
HistoIndex	1225
HistoSonics Inc.	1304
ICE-HBV	850
ICON	818
IIAM	1203
Intercept Pharmaceuticals, Inc.	1111, 1129, MR18, MR20
Inventiva Pharma	1445
Ipsen Biopharmaceuticals Inc.	1211, MR25, MR3, MR4
KAIZEN USA	1825
KlinEra	1023
Labcorp	1022
Lambda Biologics	1830
Liver Action Network-GLI	751
Livivos Inc	1321
Luminos Pro	1617
Madrigal Pharmaceuticals	1239, MR5, MR6, MR33
Mallinckrodt, Inc.	1329, MR1, MR27
Mayo Clinic / Referring Provider Office	1205
Metabolic Solutions	1725
Metware Biotechnology Inc.	1224
Miltenyi Biotec	1413
Mindray	1629
Mirum Pharmaceuticals	839, MR10, MR26, MR8

COMPANY NAME	BOOTH NUMBER
Mosaic Cell Sciences	1425
NASH kNOWledge	848
Nordic Bioscience A/S	951
Northwell Health	1615
Northwestern Medicine	1017
Novo Nordisk, Inc.	1529, MR29, MR30
Ocelot Bio	1305, MR21
Orphalan US	1731, MR14
Owlstone Medical	1018
PathAI	1645
Patient Advocate Foundation	1052
PBC Foundation	747
PBCers Organization	955
Perspectum	1238
PhoenixBio	1831
Powered Living Inc.	1117
Predictive Health Intelligence	1411
ProSciento	1633
PSC Partners Seeking a Cure	957
Recordati Rare Diseases	1431
REGENERON	1843, MR13
Research Diets Inc.	1832
Resoundant Inc.	1121
Revvity	1031

COMPANY NAME	BOOTH NUMBER
Ria Health	1427
Rocky Mountain Poison and Drug Safety	726
Salix Pharmaceuticals	939
Siemens Healthineers	921
SOLDA	748
Sonic Incytes	1450
Summit Clinical Research	1112
SuperSonic Imagine	1625
Syncell Inc.	1013
Takeda	945, MR15
Takeda Transplant	1551
Target RWE	1650
The HealthWell Foundation	720
TransCure bioServices	1826
UC San Diego Health–Liver Transplant	719
Ultragenyx	1839
United Porphyrias Association	724
UPMC Presbyterian	822
VCU	1152
Vir Biotechnology, Inc.	1110, MR41, MR42
Wolters Kluwer	1105
World Gastroenterology Organisation	730
WuXi AppTec	1841
Wuxi Hisky Medical Technologies Co., Ltd.	1019
Yecuris	1150

NOTES

Lined area for notes, consisting of multiple horizontal lines extending across the page.

FEBRUARY 27-MARCH 1, 2025

**MASLD, MetALD,
and ALD Emerging
Topic Conference**




MAY 3-4, 2025

**Basic Science
Emerging Topic
Conference**



Making an Impact, Together at
The Liver Meeting® 2025

AASLD
The Liver Meeting®



NOVEMBER 7-11, 2025 ● Washington, DC
Stay informed by joining The Liver Meeting email list.

